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ABSTRACT

COMPACT GENE REGULATORY CASSETTES SUPPORT HALLMARK FEATURES OF
T-CELL RECEPTOR (TCR)-α GENE LOCUS CONTROL REGION (LCR) ACTIVITY
by
JORDANA LOVETT
Advisor: Dr. Ben Ortiz
Despite the promise of emerging stem cell transplant gene therapy strategies, there
remains a gap in the ability to predictably generate robust, temporally controlled longlasting, therapeutic gene expression in specific target cell lineages following stem cell
differentiation. There exists a locus control region (LCR) in the mouse T-cell receptor
(TCR)-α locus that confers an αβ TCR-like spatiotemporal expression pattern upon a
linked transgene, regardless of its site of integration in the genome. These properties are
well suited to direction of high-level, physiological expression of therapeutic antigen
receptor genes to the T cell progeny of vector-transduced stem cells. The endogenous
LCR spans over 12.5-kb of DNA. To accommodate LCR activity within the space
constraints of gene delivery vectors, we aim to reduce the size of the LCR, while
retaining its characteristics. Mini-LCRs have been constructed with varying combinations
of previously characterized sub-elements of the TCRα LCR, ranging in size from 1.3- to
4.0-kb. These mini LCRs are tested in an in vitro mouse embryonic stem (ES) cell
differentiation system for their ability to recapitulate hallmark LCR properties. In T cells
derived from ES cells, reporter gene expression driven by TαLCR4.0 approximates that
observed in the presence of the full length LCR, in that TCRα LCR-linked reporter gene
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expression levels are robust, mostly cell type-restricted and are upregulated during the
expected stage transition of T cell development. Reporter gene expression driven by a
smaller mini LCR, TαLCR1.3, while robust in all clones, displays early activation
kinetics suitable for directing therapeutic gene expression to correct inherited
immunodeficiency. TαLCR2.9 and TαLCR3.0 drive tighter spatiotemporal expression by
restoring deleted elements from TαLCR1.3, and two other mini LCR cassettes have been
designed to further narrow down the sub-elements conferring function. This
structure/function information contributes to characterization of the elements of TCRα
LCR, and can enable a better understanding of the basic scientific mechanisms
underlying the gene regulation in the TCRα locus. Furthermore, incorporating TCRαderived mini LCRs into gene delivery vectors may provide the controlled and predictable
therapeutic gene expression required to overcome some of the current hurdles to the use
of genetically engineered stem cells as vehicles for delivering T cell gene therapy against
cancer and a variety of other diseases.	
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Chapter 1. Introduction
1.1 Genomic landscape and regulation

The complex and dynamic nature of the eukaryotic genome necessitates the juxtaposition of
genes with disparate functions in space and time on the chromosome. This seemingly random
landscape therefore requires high-level regulation yielding appropriate gene expression patterns.
As such, there exist cis-acting DNA elements that act as molecular switches, turning genes on
and off in a predictable and specific manner. Many of these elements function by directly
altering the activity of RNA polymerase thereby influencing the production of transcript. Such
elements include promoters and enhancers, which can bind to transcription factor complexes and
in turn modulate RNA polymerase binding. Others, such as insulator elements, or trans-acting
factors like histone or DNA modifying enzymes1, can enable epigenetic modifications to the
DNA2, 3, affecting the accessibility of the chromatin to RNA polymerase and its associated
factors. Chromatin accessibility is dictated largely by the way it is wrapped around histone
proteins4. In its heterochromatin state, DNA is tightly bound to histones, making it difficult to be
transcribed. In contrast, euchromatin is more loosely packed, permitting the binding of
transcription machinery and thus gene expression. Both states are associated with various
modifications made to the DNA or histones- these marks can facilitate differential affinities for
the histones, based on electrostatic charges, and inter-nucleosomal interactions5.

Gene regulation can also be mediated via long-range chromatin interactions that can render
entire gene loci either permissive or non-permissive for transcription6. These interactions are
largely responsible for the 3D genome architecture and formation of chromatin hubs. When
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distal regions of DNA are brought into close proximity via protein-protein interactions, gene
expression can be positively or negatively influenced. DNA looping can bring entire
chromosomal regions to the nuclear periphery, rendering them non-amenable to transcription6.
Alternatively, looping can poise a gene for transcription by enabling the formation of
transcription complexes at a particular locus by bringing distal elements, such as promoters and
enhancers, into closer proximity6.7 Higher-order chromatin structure can be understood at the
level of topologically associated domains (TADs), which describes the broader chromosomal
interactions that are associated with active or inactive domains8. The boundaries of TADs may
be associated with insulator-like elements that can establish barriers between neighboring
regions9.

The complexity underscoring the dynamic nature of eukaryotic gene expression necessitates
regulation at the local genomic region as well as the higher-order, three-dimensional structure.
The integration of these instructions allows for proper expression of genes in space and time. It is
therefore of great importance to understand the underlying mechanisms of gene regulation, given
its role in development and homeostasis.

1.2 Locus Control Regions

Oftentimes, it is the synergistic effects of multiple regulatory elements that are responsible for
the overall patterning of a particular gene’s expression. There exist elements, however, that can
encompass the properties of multiple regulatory regions. One such element, the Locus Control
Region (LCR), acts to confer multi-layered regulation upon a linked gene10. LCRs are
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conglomerates of DNase hypersensitive sites (HS) that can be identified and characterized
individually. Together, however, the sites can enhance and drive regulation of a linked gene in a
pattern that is reflective of its locus of origin10, 11, 12, 13. Within the scope of an LCR lies the
ability to drive copy number dependent, spatiotemporally specific expression of a linked
heterologous gene, regardless of its genomic integration site14. These functions are mediated by
multiple transcription factors that bind at various regions of the LCR.

The first LCR was discovered in the human β-globin locus14. Patients afflicted with γβ
Thalassemia had intact β-globin genes, but suffered from deletions in regions upstream15. This
moved scientists to extend their search beyond the coding region of the locus, and further
upstream into non-coding regions. It was there that they discovered five HS that collectively
supported the spatiotemporal gene expression pattern of the locus14. These regions impacted
hematopoiesis from as early as fetal development. Human hematopoiesis occurs with the stepwise activation of five genes within the globin locus (ε, Gγ, Aγ, β, and δ), which are responsible
for the generation of functional hemoglobin, which carries oxygen on red blood cells. Each gene
is responsible for the expression of globin at the various sites of hematopoiesis, beginning with
the yolk sac (ε), transitioning to fetal liver (Gγ, Aγ), and ultimately occurring in the bone marrow
in mature humans (β or δ). The switching of the activation of these genes, and thus the proper
expression of globin, is mediated by the upstream HS16. Deletion of portions of these sites results
in low-level, inconsistent gene expression, which can be rescued by inclusion of deleted gene
fragments, indicating the importance of proper globin gene regulation in the processes of
development and hematopoiesis. Characterization and analyses of these HS yielded what are
now known as the hallmarks of LCR activity; the ability to promote predictable gene expression
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that mimics the tissue restriction, and developmentally-timed patterns of the endogenouslylinked gene irrespective of the position of integration of the transgene in the chromatin.
Additionally, the mRNA expression level of a gene linked to the LCR will be linearly correlated
with number of genomic transgene integrants.

Since the discovery of the β-globin LCR, other LCRs have been identified and studied
(including, but not limited to, human CD217, human HLA-B718, human growth hormone19, and
mouse T cell receptor α [TCRα])20. These LCRs have classically been studied using transgenic
mouse models that allow for analysis during the development of the animal. More recently, an
embryonic stem cell differentiation model was introduced to enable a more cost effective, less
protracted experimental setup21. This system mimics mouse hematopoiesis in vitro over the
course of 21 days, and allows for the generation and assay of lineages of hematopoietic origin
such as erythrocytes, monocytes, and T cells21, 22. It allows the cis elements under study to
experience the developmental cues and priming that might be essential for their function. The
system is amenable to testing varying LCR constructs, and is not reliant upon the generation of
transgenic mouse lines.

1.3 TCRα LCR and its genomic locus

There exists an LCR in the TCRα-Dad1 locus on mouse chromosome 1420 (Figure 1). TCRα and
Dad1 have unique expression patterns and different functions depending on space and time23.
TCRα is a subunit of the αβ T cell receptor complex that mediates T cell interaction with major
histocompatibility complex (MHC)-bound antigen on cells, making TCRα largely responsible for
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the functional maturation of T cells as well as initiating the immune response. Endogenously, it
is upregulated at a late stage of T cell development. Dad1, on the other hand, is ubiquitously
expressed, at an earlier time point in development. It is known to be involved in N-linked
glycosylation as well as preventing apoptosis24,

25

. Given the two disparate functions and

expression patterns of these neighboring genes, it was hypothesized that there must exist an
element that can separate the observed spatiotemporal specificities. The DNA that occupies the
genomic territory in between these two genes is a compilation of cis regulatory elements that
have been identified by their hypersensitivity to DNase I. Together, these HS can work to yield
proper TCRα regulation, and to maintain the differential expression patterns of TCRα and Dad1.

Figure 1. TCRα-Dad1 genomic locus.
DNase HS of the TCRα LCR indicated by vertical arrows. Eα, the classical enhancer is depicted
by the dark grey box. Solid blue boxes represent the exons of TCRα and Dad1. Horizontal
arrows indicate transcriptional directionality of gene.
TCRα LCR is composed of nine DNase I Hypersensitive sites20, 23. Structure-function analyses of
these HS have thus far revealed four HS that are essential for full LCR activity, namely HS1,
HS1’, HS4 and HS626, 27, 28. The 5’ HS (HS1, HS1’) confer the spatiotemporal specificity as well
as copy number dependent aspects of LCR activity, while the farther 3’ HS (HS4, HS6) maintain
the chromatin-opening capabilities of the LCR. HS2, HS3 and HS5 have not yet been shown to
possess any specific functions. HS7 and HS8 are proposed to be silencers

26, 29

, but thus far

appear to be dispensable for complete LCR activity, in vivo26. Establishing LCR cassettes that
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could harness the properties of the essential HS to drive high level, predictable, and specific
expression of a transgene could be relevant in the gene therapy space to mitigate some of the
risks of the current treatments.
1.4 Translating LCRs for use in gene therapy

LCRs have been exploited in the field of gene therapy in order to drive predictable therapeutic
gene expression from viral vectors30. Viral vectors bearing components of the β-globin LCR
have demonstrated varying levels of success, where they have been shown to restore β -globin
levels in thalassemic mice30. The β-globin levels achieved in mouse studies, however, were
insufficient for human treatment, and thus larger subregions of HS, as well as the chicken HS4
insulators were added to boost response31, 32, 33. Attempts to test regulatory sub-components of
other LCRs (hADA, hCD2) for therapeutic purposes have also been made, and can drive
position-independent, tissue-specific expression in vitro34, 35, 36, but have yielded limited effects
in in vivo models, with limited transgene expression which was not copy-number dependent37 .
Other applications of gene therapy, currently use more constitutively active regulatory elements
to drive gene expression. Of particular interest is immunotherapy, wherein the patient’s immune
system is harnessed to fight against certain diseases.

In particular, engineered T cells that recognize specific antigens are now being used in humans to
fight forms of cancer and other conditions38,

39

. Chimeric Antigen Receptors (CARs) are

designed to bind to cell surface proteins on subsets of patients’ cells and initiate an immune
response that will eradicate them. For the purpose of gene therapy, CAR transcription units can
be introduced into a patient’s T cells ex vivo, after which the CAR-expressing cells can be
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infused into the patient. It is important to introduce these CAR transcription units only into T
cells, however, because they are widely active, and could be expressed in many cell lineages
other than T cells, and at all times. This could result in the targeting of inappropriate cell types to
tumor cells. Additionally, CAR-driven genes might be subject to position effects at their site of
integration in the genome, as vectors are un-insulated. This might cause vector silencing, and
unpredictable longevity of CAR+ T cells in transplant recipient. Indeed, this issue is already
manifested in the highly variable data on the persistence of CAR+ T cells in a patient40. The
longevity of the treatment is often associated with T cell persistence or exhaustion. Even if the T
cells remain in circulation, however, there is a possibility that they will not express the
engineered therapeutic gene if it is integrated into an inaccessible DNA region or due to
epigenetic silencing. The ability of the TCRα LCR to dictate the predictable, spatiotemporally
restricted expression of a T-cell receptor seems tailor-made for the purpose of targeting the
expression of a chimeric receptor, given the T-cell receptor’s role in mediating the immune
response against selected antigens. As such, linking the TCRα LCR to a CAR, or another
therapeutic gene, can add a layer of regulation and specificity to the T cell gene therapy platform,
which can improve safety and efficacy of the therapeutic model. It is known that expression of a
TCR in the incorrect cell type, or at an early stage of T cell development can be deleterious, and
can even lead to malignancies41, 42. Accordingly, the TCRα LCR can drive T cell specific
expression of a linked gene to mature T cell populations, which can address this concern. In
addition, TCRα LCR’s ability to modulate gene expression that is resistant silencing can improve
the efficacy and duration of response in this model.
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Therapeutic gene delivery, in the context of CARs, is administered via patient T cells, which can
recognize and target desired cell populations for elimination. Peripheral Blood Mononuclear
cells (PMBCs), from which T cells can be derived, are isolated from the patient. These T cells
can then be transduced with viruses (such as lentivirus) containing the therapeutic gene of
choice, and expanded ex vivo before being re-infused into patients. Transduced T cells, when put
back into patients, have been very successful in clearing blood cell tumors43, 44 (Figure 2).

Figure 2. T cell transfer for CAR immunotherapy.
T cells are derived from patient blood, and engineered to express a particular Chimeric Antigen
Receptor (CAR). CAR-expressing cells are selected and expanded, after which they can be
infused back into the patient. (Adapted from 45)

	
  

8	
  

There is varying data, however, as to how long these “therapeutic T cells” will remain in
circulation, ranging from months to up to 4 years, depending on the trial and tumor type
(reviewed in

40

). If circulating T cells do not persist for a long enough period to fully clear a

tumor, patients might require reinfusion with a new pool of cells, which is labor intensive, and
costly. Alternatively, therapeutic cells that circulate beyond tumor clearance might result in
depletion of off-target cells, inducing negative side effects. In order to provide a renewable
source of engineered T cells, it might be advantageous to transduce a stem cell population that
will remain present for the duration of the patient’s lifetime. Insertion of therapeutic genes into
these populations, however, may result in the expression of the gene in all the progeny of the
stem cell source, potentially directing of all cells derived from the source to the selected target,
which might be deleterious in the clinic. Alternatively, when randomly integrated into the
genome, therapeutic genes might be silenced over time, thereby eliminating their clinical impact.
It is therefore essential to reconcile the need for long-term therapy with targeted, predictable
expression to specific cell lineages. Utilizing the properties of TCRα	
   LCR seems to remedy some
of the current limitations associated with existing therapeutic models: therapeutic gene-bearing
vectors including TCRα LCR-derived elements can be used to transduce HSCs, as they should
produce cargo gene expression that mimics cell type- and developmental timing-specificity of
the TCRα. Namely, only T cells that emerge from transduced HSCs will express the therapeutic
gene at the proper stage of T cell maturation. Additionally, the LCR will introduce yet another
layer of protection to the linked therapeutic gene; it will enable expression from any integration
point within the genome, that will be resistant to chromatin-induced silencing, which can impact
the durability and efficacy of the response.
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CARs, or other therapeutic genes must be introduced to a patient’s cells in safe and efficient
ways. While there exist various gene-delivery vehicles, viral vectors are a popular way to
introduce genes into cells. In particular, lentiviral vectors have been useful for their ability to
stably integrate into the genome of non-dividing cell populations, such as hematopoietic stem
cells. Lentiviral vectors, however, can hold up to approximately 8kb of exogenous DNA without
compromising packaging ability46. Beyond this DNA limitation, the efficiency of the virus to be
assembled is significantly lessened. This 8kb limit is exceeded by that of the TCRα LCR, as it
spans 12.5kb in the genome20. Therefore, in order to make this gene regulatory element
amenable for use in these vectors, it is necessary to reduce it in size, while retaining its ability to
drive predictable gene expression patterns. To accommodate this limitation, only the portions of
the TCRα LCR that have been shown to have functional importance have been included within
‘mini LCR’ constructions, which can be incorporated into lentiviral vectors. The largest of the
mini LCRs, made by Dr. Armin Lahiji, includes the four HS regions (HS1, HS1’, HS4, HS6) that
have been demonstrated to contribute to the spatiotemporal specificity, and/or chromatin opening
functions of the LCR in transgenic mouse models26, 27, 28, 47. This mini-LCR is only 4kb, which
represents a reduction of over 70% of the full-length 12.5kb TCRα LCR, and is small enough to
be incorporated into a lentiviral vector. Other variations of these mini-LCRs include further
reduced sub regions of the required HS. These mini LCRs can be tested for their ability to
recapitulate full LCR activity, and drive reporter gene expression with expected TCRα-like
patterning, through development in an in vitro differentiation system, and when transduced into a
stem cell population.
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This study, therefore, addresses both basic and translational applications of the regulatory
function TCRα LCR, enabling a two-pronged approach in addressing biological questions and
applying the resulting knowledge for tangible solutions. Firstly, we aim to minimize the LCR
DNA without compromising classical LCR properties. Various permutations and deletions of
HS, or portions of HS, will be combined into ‘mini LCRs’, which can be assessed for their
ability to recapitulate full LCR activity. This aspect of the project will elucidate which TCRα
LCR components are necessary and sufficient, and can help us begin to understand the possible
interplay between them. In addition to this contribution to basic science, these mini LCRs might
be clinically relevant for use in gene therapy. We explore their potential to be incorporated into
lentiviral vectors, in order to regulate a linked therapeutic gene in a TCRα-like pattern. In this
way, we achieve a better understanding of the underlying regulatory mechanism of the TCRα
LCR, while also aiming to make it translationally applicable.

Chapter 2. From stem cells to T cells
2.1 ESCs

Embryonic stem cells (ESCs) are derived from the inner cell mass (E3.5) and are characterized
by their pluripotency and ability to self-renew48, 49. These cells can give rise to all three germ
layers in a developing embryo in vivo. In vitro, ESCs can be maintained in their pluripotent state
by culturing them on a feeder matrix and with the addition of leukemia inhibitory factor (LIF)50.
Removal of these conditions results in the spontaneous differentiation of the cells into embryoid
bodies, three-dimensional aggregates of ESCs that possess the potential to contribute to a
heterogeneous cell population, including blood mesoderm precursors, endoderm, and
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hematopoietic lineages51. The microenvironment and the factors52 within it contribute to the
determination of lineage choice. These circumstances can be manipulated in vitro in order to
derive particular cell types.

2.2 Hematopoiesis

Hematopoietic precursors also have the ability to self-renew in their multipotent state, as well as
give rise to all blood lineages. Hematopoietic development in the mouse begins at E7.5 in the
yolk sac, which is the site of primitive hematopoiesis. This stage occurs only early in
development, and is typically restricted as to the types of blood cells (generally red blood cells
and macrophages) that emerge. The transition to the aorta-gonad-mesonephros (AGM) region
marks the switch to definitive hematopoiesis, around E10.5 where the first emergence of
hematopoietic stem cells (HSCs) occurs53, 54. These HSCs seed the fetal liver, and ultimately the
bone marrow, where the hematopoietic niche is established and maintained throughout
development.

The bone marrow niche is supported by cellular constituents (such as

osteoblasts55), as well as other factors such as cytokines and chemokines (which drive
differentiation to specific cell-types)56, 57, protein factors, as well as oxygen and calcium levels58,
59

. Together, these components provide the micro-environment that is necessary for

differentiation of blood lineages60.

Within the bone marrow, HSC pools are maintained via self-renewal, or are able to differentiate
depending on environmental cell fate determination. HSCs are mostly quiescent, and divide
rarely in order to regenerate the stem cell pool61. Bone marrow HSCs can further differentiate
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into multipotent progenitors (MPPs), which give rise to the common myeloid progenitors
(CMPs) and common lymphoid progenitors (CLPs). CMPs, upon subsequent development, can
yield myeloblasts (including monocytes), mast cells, megakaryocytes, and erythrocytes. CLPs,
on the other hand, give rise to natural killer, dendritic, B and T cells. Niche conditions as well as
the factors available within are largely responsible for the hematopoietic fate of these cells.
Many hematopoietic lineages can be derived from ESCs in vitro by mimicking the signals
experienced in vivo through development62.

2.3 T cell development

A small subset of CLPs is able to migrate and settle in the thymus, a process supported by the
expression of particular cytokines, and chemokine receptors. Progenitors expressing fms-like
tyrosine receptor-3 (Flt3) at high levels are better suited for migration out of the bone marrow
into the thymus63. The expression and signaling of Flt3 in these precursors promotes chemokine
receptors CCR9 and CCR7 production, both of which are essential for thymic homing and
settling64, 65. Early settlers of the thymus retain the potential to generate other alternative lineages
(namely, myeloid, natural killer, but not B cells), which is lost over time, a process likely
supported by the thymic microenvironment66.

The Notch signaling pathway has been identified as a strong inhibitor of non-T cell lineages
within the thymus67, 68, and is known to be responsible for many cellular bifurcation decisions68,
69, 70, 71

. There exist four Notch receptors, as well as two families of Notch ligands, Delta-like

(DL) and Jagged. Upon ligand binding, the intracellular domain of the receptor is cleaved and
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enters the nucleus, binding to transcription factors to alter gene expression. During T cell
development, Notch 1 is the receptor that is both necessary and sufficient to drive
differentiation67, 68. When this receptor is bound by its ligand in CLPs, genes that positively
influence T cell programs are upregulated, while the B cell program is strongly repressed.

The development of the two major types of T cells, αβ and γδ, is supported by the
microenvironment of the thymus. The framework of this niche, which includes cell-cell
interactions, signaling, and presence of specific factors, is responsible for the differentiation,
commitment, and maturation of these cells. The maturation of developing T cells is dependent
upon the expression of TCR, CD4 or CD8, which are essential for interaction with self-major
histocompatibility complex (MHC) proteins. This interaction and engagement of the TCR with
MHC dictates the subsequent positive and negative selection processes through the development
and functional maturation of these cells.

2.4 Doing it in a dish: ESC to T cell differentiation in vitro

The ability to mimic the hematopoietic niche has been harnessed to drive the differentiation of
stem cells into multiple hematopoietic lineages, such as erythroid, monocytic, and B cells62.
More recently, a cell culture system to derive T cells from stem cells was developed, enabling
the study of their development in vitro22 (Figure 3). This system exploits Notch signaling to
recapitulate the thymic environment in which T cells become committed22, 72.
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Figure 3. OP9-DL1 system for in vitro differentiation.
Transfected ESCs are seeded onto OP9 cells. As the co-culture progresses, Flt-3L and IL-7 are
added to promote hematopoietic cell and lymphoid cell differentiation, respectively. Cells can
continue to grow on OP9 (GFP) cells for erythroid and monocytic lineage generation, or can be
transferred onto OP9-DL1 cells in order to promote T cell differentiation. Cells may be analyzed
for reporter gene expression at various time points via flow cytometry using indicated markers to
identify cell populations.
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ESCs are co-cultured with a bone marrow derived cell line (OP9-GFP), providing the signaling
to initiate the hematopoietic program22, 73. These cells are macrophage colony-stimulating factor
(MCSF)- deficient, such that the generation of macrophages is not favored at the expense of
other hematopoietic lineages62, 74. OP9 cells endogenously express the Jagged ligand for the
Notch receptor, which alone is insufficient for derivation of T cells. Therefore, OP9 cells were
retrovirally transduced with the Delta-like 1 ligand to yield the OP9-DL1 cell line upon which T
cells can be generated22, 73, 75.

Upon removal of LIF, ESCs begin to form blood-mesoderm-like colonies, which can in turn give
rise to hematopoietic progenitor cells, when cultured on the bone marrow stromal cell line. The
addition of Flt3L and IL7 support the development of T cells on OP9-DL1 monolayers, and other
blood lineages with continued culturing on OP9-GFP cells (protocol outlined in

76

).

The

emerging cells can be identified by the markers on their cell surfaces. For example, cells can be
distinguished by their absence or presence of CD45, as well as expression of Ter119
(erythrocytes) or CD11b (monocytes). T cells undergo a sequential acquisition or loss of
particular cell surface markers that are indicative of their stage of maturation. T cells initially
undergo four “double negative (DN)” stages, when they are negative for both CD4 and CD8. The
four stages can be further subdivided by the differential expression of CD44 and CD25. T cells
then progress to the “double positive (DP)” stage, at which both CD4 and CD8 are expressed.
Loss of either CD4 or CD8 renders the T cells “single positive (SP)” for CD4 (helper T cells) or
CD8 (cytotoxic T cells). This system only yields CD8 SP cells because of the lack of MHCII
expression on OP9 cells, which is required for CD4+ T cell generation. Reporter gene expression
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can be tracked throughout development via flow cytometry, and analyzed for adherence to
hallmark LCR properties.

Chapter 3. Characterizing TCRα LCR using in vitro ESC differentiation
3.1 TCRα LCR HS composition and function
	
  

Figure 4. Functional hypersensitive sites of the TCRα LCR.
Schematic representation of TCRα LCR, where colored boxes indicate the DNase HS that have
been functionally characterized. HS1, or Eα is the classical enhancer of the LCR. Along with
HS1’, it confers the spatiotemporal restriction associated with LCR activity. The dotted box
within HS1’ represents DNA 3’ to CTCF sites that is not included in a subset of mini LCR
constructs. HS4 and HS6 are responsible for suppression of position effects. Dotted lines within
HS6 represent functional regions TF123 and HS316. In a subset of mini LCR constructs, only
sub regions TF123 and HS316 are included.
Within the TCRα-Dad1 locus, which resides on mouse chromosome 14, there exist a
conglomerate of cis regulatory elements that comprise the T-cell Receptor α Locus Control
Region20. The TCRα LCR is composed of nine DNase I hypersensitive sites (HS1-8), some of
which have been functionally characterized. The 5’ region, composed of HS1 and HS1’, is
responsible for the spatiotemporal control as well as copy-number dependent qualities associated
with the LCR26,

29, 77

. Farther 3’ sites, HS4 and HS6 are thought to confer the position

independence of the LCR-linked transgene27, 28, 47, 78 (Figure 4). The hallmarks of LCR properties
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are seemingly maintained within these HS, however, it has thus far not been shown if only HS1,
HS1’, HS4, and HS6 alone can sufficiently confer position-independent, spatiotemporallycontrolled expression patterns on transgenes.

HS1, or Eα, contains the classical enhancer activity associated with the LCR29. Along with HS1’,
HS1 yields the temporospatial control associated with LCR activity26. Within HS1’ exist two
CTCF binding sites, which are not required for LCR activity28. CTCF, however, is a protein that
has been widely studied and implicated for its role in establishing histone modifications79, as
well as establishing loops and inter-domain boundaries in the larger-scale DNA architecture80, 81.
Moreover, if bound to an insulator element, it can establish an active boundary between
enhancers and promoters, thus establishing barriers between neighboring genes79, 80.

Further 3’, HS4-region DNA has been shown to be essential for LCR activity and is selectively
demethylated in lymphoid organs47. DNA methylation is often correlated with a closed
chromatin structure that is inaccessible to transcription factors82, whereas a hypo-methylated
region can be more readily available. Its differential methylation status suggests that it renders
chromatin selectively accessible to transcription factors and other transcription machinery
throughout various cell lineages. Notably, the establishment of this tissue-dependent methylation
is dependent on the presence of HS1’47. Deletion of HS4 reduces LCR activity, and can render a
gene subject to position effects, as measured by transgene expression28.

Position effects refer to the impact of the genomic surroundings upon the expression of an
integrated transgene. If integrated into a non-permissive region, gene expression can be
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silenced48, however if a gene inserts within an accessible region, it might be expressed, and
potentially influenced by the neighboring elements83. Therefore, the site of genomic integration
can dictate whether or not a gene will be expressed or silenced. HS6 alone has the ability to
overcome position effects, and plays a role in preventing the encroachment of silencing
heterochromatin upon a transgene27, 78. Specifically, there are two sub-regions within HS6 that
are required for this activity. TF (Thymic Footprint)-1-2-3 is a region that consists of three
factor-binding sites, each of which binds to factors involved in chromatin remodeling78. TF2
binds to AML/Runx1 proteins, while TF3 binds Elf1, a member of the Ets protein family27. In
addition to the three thymic footprint regions, there is a 316-bp region that is required for highlevel transgene expression in mice. Deletion of the TF123 or the 316-bp region within HS6
results in significantly reduced transgene expression, likely owing to the inability of the LCR to
properly regulate expression-favoring chromatin conformations27.

In the absence of HS1’,

however, the activity of the LCR-linked transgene becomes widespread27. HS7 and HS8 contain
silencer region20, and are dispensable for LCR activity77. Thus far, the function (if any) of the HS
2,3, and 5 regions has not been determined.

Because the LCR is able to exert its functions upon a linked transgene in the TCRα position, it
can be utilized to drive reporter gene expression with a TCRα-like spatiotemporal pattern. While
it is known that HS1, HS1’, HS4, and HS6 contain the properties associated with hallmark LCR
functions, it is heretofore unknown whether these HS alone can provide such regulation in
combination with one another. Furthermore, testing of different combinations of these sites,
along with sub-HS deletions thereof, can add to the understanding of how each element
contributes to overall LCR capabilities, including potential redundancies, and synergies. The
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application of the data acquired from TCRα LCR studies can allow for the generation of mini
LCRs containing only a subset of varying characterized HS. Studies can yield information on the
basic structure-function of LCR elements, as well as utility in a translational approach, where the
LCR can be linked to a heterologous therapeutic gene in an immunotherapy setting.

3.2 Honey, I shrunk the LCR: generation of mini-LCRs

The endogenous TCRα LCR spans over 12.5kb in genome20. The sites lying within this range
together, and potentially with the help of other elements, can drive the gene expression pattern of
the neighboring TCR gene. Structure/function data describing the activity of particular HS were
utilized in the construction of various mini LCR cassettes. Each mini LCR will consist of various
HS (and sub-HS), and are designed to test if particular HS are sufficient to reproduce full LCR
activity. These constructs will further test and dissect HS1’, HS4, and HS6 regions for their
ability to work in concert and in assorted arrangements. Dissection of HS guided by years of
characterization to further reduce the known functional regions, can pinpoint activity to a
narrower sequence. Deletion, or inclusion of only conserved regions within other HS can yield
interesting knowledge on its relevance, or potential redundancy and possible interactions within
the LCR. Mixing and matching these altered HS can provide significant data and insight into the
inner-workings of the LCR. Not only can we use these cassettes to identify necessary and
sufficient HS, but once mini LCRs are generated that can amply recapitulate full LCR activity,
they will be within the size confines for incorporation into viral gene therapy vectors for use in
the treatment of genetic insufficiencies and diseases. Gene therapy vectors are capable of holding
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only limited amounts of exogenous DNA, so condensing the LCR would be essential for
packaging and utility in a therapeutic model.

Figure 5. Mini LCR constructs.
Constructs were generated and incorporate varying combinations of HS1, HS1’, HS4, HS6, and
sub-regions within these HS. All cassettes include the HS1 core enhancer region. In addition to
HS1, TαLCR4.0 includes the full HS1’, HS4, and HS6. TαLCR3.0 and TαLCR2.9 include the
full HS1’, and HS6, but the former includes an HS4 homology block, while in the latter, HS4 is
not included at all. A sub-element of HS1’ that includes all DNA until the CTCF site is utilized
in TαLCR2.6 and TαLCR1.3. Only TF123 and HS316 regions of HS6 are utilized in TαLCR1.6
and TαLCR1.3. Mini LCR constructs are linked to a hCD2 reporter gene driven by the hCD2
promoter.
In accordance with the aforementioned objectives, five mini-LCR cassettes were generated and
assayed for their ability to retain hallmark LCR properties (Figure 5). These constructs were
designed with varying HS incorporations that would help identify functional information about
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the LCR components. The largest of the mini-LCRs, TαLCR4.0 is 4kb in length and includes
HS1, HS1’, HS4, and HS6. (Lahiji, thesis 2013). The smallest of the mini-LCRs is 1.3kb long,
containing only sub-elements residing in HS1, HS1’, and HS6, shrinking the size of the LCR by
nearly 80% (Lahiji, thesis 2013). These sub-elements were chosen based on structure-function
studies done previously in the lab. They include all DNA of HS1’ 5’ of the two CTCF sites
(including both the canonical and non-canonical CTCF sites), and the TF123 and HS316 regions
of HS6. Both TαLCR4.0 and TαLCR1.3 were designed and constructed by Dr. Armin Lahiji. HS
and their sub-regions were assembled in varying combinations in order to test individual regions
for their ability to contribute to LCR activity. In one, TαLCR2.9, DNA 5’ of the CTCF site in
HS1’ as well as all excluded DNA from HS6 was included to yield a construct containing a full
HS1, HS1’, and HS6. This construct tests whether HS4 is necessary for providing predicted
TCRα-like expression patterns. Based on bioinformatics analyses of homology between the
murine and the human TCRα LCR sequences, a mini LCR (TαLCR3.0) was generated that
contains the complete HS1, 1’, and 6 regions along with the homology block of HS4 (Valia
Kostyuk). This was made based on the hypothesis the homology regions would be conserved
based on their importance in retention of HS4 function (Figure 11, page 33). Yet another
cassette, TαLCR1.6, was built to test whether the end of HS1’ contained the activity necessary
for full LCR function. This contains the full HS1, HS1’ and only the TF123 and HS316 regions
of HS6. If, indeed, LCR-conferred properties are exhibited by reporter gene driven by
TaLCR1.6, it demonstrates importance for the 3’-most region of HS1’. Lastly, if the deleted
regions of HS1’ failed to restore LCR activity, the function might be held within the portions of
HS6 that lie outside of TF123 and HS316. Therefore, TαLCR2.6 was created to contain a
restored HS6 with a reduced HS1’.
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3.3 TαLCR4.0
	
  
	
  
Four of the nine DNase I HS were chosen for incorporation into the largest of the mini LCRs
based on structure/function analyses from our lab and others. ESCs were co-transfected with
hCD2 reporter84-linked TαLCR4.0 and a neomycin resistance gene. Upon G418 selection,
individual ESC colonies were picked and screened via PCR and Southern Blot. Positive clones
were subject to differentiation via the OP9-DL1 system, and driven to erythrocytes, monocytes,
and T cells. Over the course of the 21-day differentiation, hallmark spatial and temporal LCR
properties are assessed via flow cytometry at various time points. On the final day, total RNA is
collected, and measured via qRT-PCR to assess for copy number dependence.
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Figure 6. TαLCR4.0 drives expression of a reporter TCRα-like spatiotemporal patterning.
Histograms reflect hCD2 reporter gene expression in T cells, erythrocytes, or monocytes derived
from ESC differentiation using the OP9-DL1 system. The red line represents hCD2 expression in
an un-transfected clone run alongside clones bearing TαLCR4.0,	
   which	
   are	
   indicated	
   by	
   the	
  
blue	
   line. (A). TαLCR4.0-driven reporter is expressed in a TCRα-like manner, and is most
robustly upregulated in DP T cells. In erythrocytic populations derived from differentiated ESCs,
reporter expression does not exceed that observed in untransfected control. In monocytes, lowlevel reporter expression is observed in a small population of cells. (B). TαLCR4.0 displays
predicted developmental onset of reporter expression. There is no appreciable expression in early
stage T cells, whereas significant upregulation is observed at the DN3-DP transition.
Even in the absence of approximately 70% of LCR DNA, TαLCR4.0 appears to support the
spatial, temporal, and copy number dependent properties of the LCR (Figures 6,7). Additionally,
all clones expressed the transgene, indicating its ability to confer position independence. On day
12, we analyze erythrocytes (CD45-, Ter119+), and monocytes (CD45+, CD11b+), for hCD2
reporter gene expression (Figure 6A). FACS analyses of erythrocytic cells reveals that there is no
hCD2 expression above the untransfected control. There is, however, a small shift in a
population of monocytic cells that indicates ‘leaky’ LCR-driven expression. This upregulation
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might be attributed to the absence of sequences outside HS1, HS1’, HS4, and HS6 that might
further tighten the cell specificity associated with the complete TCRα LCR. Additionally, the
spacing of DNA in the endogenous locus might be required for establishment of chromatin
topology that is conducive to DNA-factor interaction, thereby facilitating expected expression
patterns. Early stage T cells (DN1: CD45+, CD44+, CD25-, CD4-, CD8-; DN2: CD45+, CD44+,
CD25+, CD4-, CD8-) were also analyzed for hCD2 reporter gene expression (Figure 6B). As per
expectations, there is no significant reporter expression prior to the predicted onset of expression.
In contrast, later stage T cell progeny DN3 (CD45+, CD44-, CD25+, CD4-, CD8-) and DP
(CD45+, CD44-, CD25-, CD4+, CD8+) cells expressed high levels of the hCD2 reporter gene
(Figure 6B). All clones that were generated and tested display similar patterns to representative
clones shown above, with the exception of a single clone, which displayed higher expression of
the hCD2 reporter gene in monocytic populations, as well as a bimodal peak observed at later
stages of T cell development. Southern blot analysis indicated that this clone, however, appears
to have incorporated truncated transgenes, and thus was excluded from the analyses.
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Figure 7. TαLCR4.0-bearing clones drive reporter mRNA expression in a copy number
dependent manner.
(A). RNA was collected from day 20 of co-cultures, which mainly consist of DP and CD8 SP T
cells, and was analyzed via qRT-PCR. To account for the heterogeneous co-culture, data were
normalized using TCRα primers. Expression is represented as percent max per copy to account
for difference in copy number among individual TαLCR4.0 clones, enabling cross-comparison
between clones. Copy number is determined from averaging Phosphorimager analyses from
three Southern Blots. The value of the highest- expressing clone is set to 100%. mRNA
expression falls within a narrow range of 1.6 fold difference indicating retention of copy number
dependence. (B). Graph of the correlation between relative mRNA level and transgene copy
number. Microsoft Excel was used to calculate x-y value correlation and (r) value (on graph).
The p value was derived from an F test on the linear relationship between x and y values and
p<0.05.

Additionally, the copy number relatedness supported by the TαLCR4.0 mini LCR is equivalent
to that of the full length TCRα LCR, with variation of mRNA levels per copy falling within a
narrow 1.6 fold range (Figure 7). It is accepted within the field that mRNA levels falling below a
3-fold range of variation are said to be copy number dependent, under ~10-fold partially copy
number dependent, and above a ~10-fold difference is outside the range of copy number
dependence85. In order to assess for this hallmark LCR feature, RNA is collected from cocultures on day 20, and subject to q-RT-PCR analysis. Typically, these cultures are composed of
mature T cells, either in the double positive, or CD8 single positive stage of development. To
account for the heterogeneous nature of the population, data are normalized using TCRα primers.
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In order to enable cross-comparison between clones of varying copy number, data are also
normalized by dividing each clone by the number of integrants, as determined using Southern
Blot analysis. This allows us to express data as percent max expression per copy (y axis). The
percent max expression per copy of the highest expressing clone can be compared to that of the
lowest expressing clone, and would be expected to fall within a narrow range (as indicated
above), if the feature of copy number dependence is retained.

3.4 TαLCR1.3
	
  
	
  
In order to further reduce the size of the 4.0kb mini-LCR, deletions were made within HS1’ and
HS6 based on previous data, and HS4 was removed to yield a 1.3kb mini-LCR. Analyses from
flow cytometry results of erythrocytes show that there is no expression of hCD2 in these cells. In
monocyte populations, however, there appears to be ectopic reporter gene expression, indicating
a loss in the ability of the TαLCR 1.3 to control the cell type-restriction of the linked gene
(Figure 8A).
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Figure 8. TαLCR1.3 drives promiscuous transgene activity in monocytes and early-stage T cells.
Histograms reflect hCD2 reporter gene expression in T cells, erythrocytes, or monocytes derived
from ESC differentiation using the OP9-DL1 system. The red line represents hCD2 expression in
an un-transfected clone run alongside clones bearing TαLCR1.3,	
   which	
   are	
   indicated	
   by	
   the	
  
blue	
   line. (A). While reporter expression is restricted within the erythrocyte lineage, ectopic
expression is seen in monocytes derived from ESCs. (B). Early activation kinetics of reporter
gene begins at the immature DN1 stage. Expression increases, as expected with T cell
maturation.
Additionally, there are early activation kinetics associated with this version of the mini LCR that
suggest that the developmental timing property of the TCRα LCR is compromised (Figure 8B).
Endogenous TCRα expression is upregulated in late-stage T cell development (DP), which is
mimicked in the in vitro differentiation system using the full-length LCR, as well as with
TαLCR4.0, where significant upregulation is initiated between DN3-DP late stage T cell
development. TαLCR1.3-driven transgene expression, on the other hand, is initiated beginning at
the early DN1 stage. Robust expression of the reporter gene is seen in more mature T cell
populations. Further reduction of HS1’ and HS6, or loss of HS4 could potentially be responsible
for the observed promiscuous activity. Extraction of mRNA from day 20 co-cultures, and
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analysis via qRT-PCR showed a loss of full copy number dependence from these cultures. A
Fold difference of 8.49 is measured, which falls within the range associated with partial copy
number dependence (Figure 9). It might be noted, based on the data below, that clones bearing
higher numbers of integrants have a lower percent max expression per copy relative to those of a
lower copy number. This phenotype might be the result of multi-copy inhibition, in which the
presence of more integrants acts to negatively impact transcription, lowering the overall
expression per copy. While this explanation is plausible, more clones with higher copy numbers
would be necessary for confirmation. Alternatively, the notion of multi-copy saturation, in which
the amount of RNA is limited after a certain number of copies, might explain this observation as
well. This can result from transcription factor or polymerase availability in the cell. While this
observation is evident in clones bearing TαLCR1.3, the same does not necessarily hold true for
TαLCR4.0. Therefore, some of the elements that are present in TαLCR4.0, but absent in
TαLCR1.3 might subject the transgene to this saturation.
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Figure 9. TαLCR1.3-bearing clones drive reporter mRNA expression in a partially copy number
dependent manner.
qRT-PCR analyses done on mRNA extracted from Day 20 co-cultures, normalized to TCRα, and
for copy number, indicate an 8.49 fold difference, indicating partial copy number dependence of
TαLCR1.3-driven reporter. (B). Graph of the correlation between relative mRNA level and
transgene copy number. Microsoft Excel was used to calculate x-y value correlation and (r) value
(on graph). The p value was derived from an F test on the linear relationship between x and y
values and p<0.05.

3.5 TαLCR2.9

In order to determine which of the deleted elements in TαLCR1.3 was responsible for the loss of
certain aspects of LCR activity, we restored the missing DNA in HS1’ and HS6 to the full
hypersensitive sites, thus yielding a mini-LCR that includes HS1, HS1’, and HS6 only. The
absence of HS4 will inform more about its relevance in providing LCR associated activity. It is
known that deletion of HS4 in transgenic mice results in low transgene expression with altered
tissue distribution28. Moreover, this activity is associated with its tissue-selective demethylation,
reliant on the presence of HS1’47. It is unknown, however, in what capacity HS4 synergizes with
other LCR elements, and the precise mechanism by which HS4 functions. Its deletion in this
context will enable a better understanding of whether HS4 is required, and which of the other HS
are necessary or potentially dispensable in its function.
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Figure 10. TαLCR2.9 displays expected onset of developmental expression, and tissue
restriction.
(A). Analysis of two clones bearing TαLCR2.9 shows restriction of transgene expression to T
cells, as minimal expression in seen in erythrocytes, and monocytes. (B). Reporter expression
driven by TαLCR2.9 is not turned on until late stage T cell development, however a bimodal
peak is observed, suggesting potential position effect variegation.
Data thus far from co-culture experiments using TαLCR2.9 constructs reveal that surprisingly,
the LCR property of spatiotemporal specificity is maintained throughout development.
Expression is not initiated until the expected DN3-DP transition (Figure 10B), albeit in a
bimodal fashion. This expression is mainly restricted to T cell progeny (not expressed in
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erythrocytes or monocytes) (Figure 10A). But the bimodal expression in later stage thymocytes
may be an indication of the transgene being subject to position effects. This is not surprising, as
HS4 deletion experiments conducted in transgenic mice resulted in reduced transgene
expression, indicating the HS4 regions potential role in positively influencing chromatin
structure in T cells28.

3.6 TαLCR3.0
	
  
	
  
Bioinformatics analysis (Valia Kostyuk) identified regions of HS4 with homology to human
sequences within this locus. Three homology blocks (blocks 296, 297, 298) with the highest
percentage of homology (of 459 analyzed blocks) were assembled to form the “hHS4” homology
unit, which was incorporated into TαLCR2.9 in the place of HS4 (Figure 11).
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Figure 11. A conserved sequence within HS4 for incorporation into mini LCR cassette.
(A). Cross-species DNA sequence analysis (including mouse/human) revealed a <200bp
fragment of homology lying within the HS4 region. (B). This region is composed of three
separate blocks, with the highest sequence homology (blocks 296 [20nucleotides, 65%
homology] (red), 297 [55 nucleotides, 62.5% homology] (blue), 298 [67 nucleotides, 60%
homology] (green)), with 57 intervening nucleotides in between blocks 297 and 298. (C).
Predicted protein binding sites within region of HS4 homology.
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Figure 12. TαLCR3.0
incorporates a homology
block residing in HS4 that
restores tissue specificity and
maintains later stage
activation.
(A). Reporter expression
driven by TαLCR3.0 is
restricted to T cell progeny of
differentiated ESCs. (B). At
early stage DN1, there is no
transgene expression, whereas
in more mature T cell
populations, there is robust
upregulation. DN4+ cells are
gated on CD25-, CD44-.

Cross-species evolutionary conservation can indicate importance and potentially function of a
sequence. Therefore, in order to minimize HS4 from 1.1kb to less than 200bp, only regions
containing human-homologous sequence were incorporated into the mini LCR. When two ESC
clones bearing TαLCR3.0	
   were	
   differentiated,	
   monocytes	
   and	
   erythrocytes	
   from	
   the	
  
emerging	
   cultures	
   were	
   negative	
   for	
   reporter	
   gene	
   expression	
   (Figure	
   12A).	
   Expression	
  
was	
   not	
   activated	
   in	
   DN1	
   T	
   cell	
   populations,	
   however	
   in	
   later	
   stage	
   pools,	
   robust,	
   rather	
  
than	
   bimodal,	
   expression	
   was	
   observed	
   (Figure	
   12B).	
   It	
   should	
   be	
   noted	
   that	
   these	
  
preliminary	
   studies	
   do	
   not	
   include	
   data	
   from	
   DN2	
   and	
   DN3,	
   which	
   would	
   give	
   a	
   more	
  
complete	
   understanding	
   regarding	
   the	
   developmental	
   onset	
   of	
   expression	
   of	
   hCD2.	
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However,	
   these	
   studies	
   generate	
   a	
   broad	
   picture	
   of	
   hCD2	
   expression	
   in	
   immature	
   (DN1)	
  
versus	
   more	
   mature	
   (DP)	
   T	
   cell	
   populations.	
   These	
   preliminary	
   data	
   suggest	
   that	
  
incorporation	
  of	
  just	
  a	
  small	
  region	
  of	
  mouse-‐human	
  homology	
  in	
  HS4	
  of	
  the	
  TCRα	
  LCR	
  can	
  
restore	
   some	
   of	
   the	
   activity	
   lost	
   upon	
   deletion	
   of	
   the	
   entire	
   HS4,	
   namely	
   the	
  
reestablishment	
  of	
  robust	
  transgene	
  expression	
  in	
  mature	
  T	
  cell	
  stages.	
  This	
  might	
  be	
  the	
  
result	
   of	
   predicted	
   factor	
   binding	
   sites,	
   which	
   can	
   harbor	
   the	
   proteins	
   that	
   can	
   be	
  
implicated	
  in	
  chromatin	
  modulation	
  and	
  T	
  cell	
  development.	
  For	
  example,	
  members	
  of	
  the	
  
RUNT	
  and	
  ETS	
  protein	
  families,	
  among	
  others,	
  have	
  been	
  shown	
  to	
  have	
  a	
  role	
  in	
  histone	
  
interactions86,	
   87	
   and	
   nucleosomal	
   positioning88,	
   which	
   can	
   directly	
   impact	
   the	
   local	
  
chromatin	
   structure.	
   Thus,	
   this	
   block	
   of	
   homology,	
   containing	
   predicted	
   protein	
   binding	
  
sequences,	
   represents	
   a	
   narrower	
   region	
   in	
   which	
   the	
   function	
   of	
   HS4	
   can	
   potentially	
  
reside.	
  	
  
	
  
3.7 Rescuing lost aspects of LCR activity: TαLCR1.6 and TαLCR2.6

An element potentially required for the restoration of lost activity seen in TαLCR1.3 is ~300bp
region 3’ to the CTCF sites in HS1’. Despite the fact that the activity of the LCR is CTCFindependent28, these sites were included in the mini-HS1’ used in the construction of mini LCRs
given the known importance of CTCF in gene regulation. Further 3’ DNA was omitted in an
effort to reduce LCR size, and to further constrain the HS defined by restriction mapping26.
HS1’ forms strongly in both lymphoid and non-lymphoid tissue, and is involved in the formation
of differential chromatin structure in HS4 and HS626. It is possibly through the control of the
local LCR chromatin landscape that it mediates the lymphoid-specific nature of TCRα. With this
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in mind, the 3’ region of HS1’ was reincorporated into TαLCR1.3 in hopes of restoring greater
cell type-specific function to the mini LCR.

The final factor that distinguishes the TαLCR1.3 from TαLCR4.0 is the full HS6. A construct
was designed to include the sub-region of HS1’ containing DNA up to the 3’ CTCF site, with
HS6 in its entirety was also generated for future testing. If LCR activity is not rescued by the
addition of the full HS1’ region, perhaps it is retained within HS6 sub-regions outside of TF123
or HS316.

The above constructs have been designed, cloned, and transfected into ESC for future
differentiation and analyses.

Chapter 4. Translating TCRα LCR for use in gene therapy
4.1 Immunotherapy: cancer and beyond

Attempts to harness the power of the immune system to fight disease have been on the forefront
of biological and clinical research for the over two decades. T cells, in particular, are being
exploited for their natural ability to recognize foreign antigen and initiate immune responses to
them. The specificity of T cells can be engineered and redirected towards the detection of cellmarkers associated with a number of diseases and genetic deficiencies, including cancer.

Among others, immune checkpoint blockade therapy and Chimeric Antigen Receptor (CAR) T
cell gene therapy have drawn significant attention for their success in clinical trials. Both
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methods rely on modifying a patient’s immune system such that it recognizes and inhibits tumor
growth. In particular CAR T cell immunotherapy has been effective in clearing certain blood cell
tumors in a number of patients. Additionally, CARs have been designed and tested for other
clinical indications such as neurological diseases (Parkinson’s Disease, Alzheimer’s Disease)89,
as well as in treatment of HIV90, 91. CARs are synthetic recombinant receptors designed to
specifically target a particular antigen. They encompass a combination of moieties that enable
antigen recognition/binding (Single-chain variable fragment (scFv)), T cell activation (CD3ζ
chain), and co-stimulation (CD28 or 4-1BB, among others) to create a functional response in
CAR-expressing T cells92. While many methods of genetic modulation have been employed to
insert the CAR into the genome, so far, one of the most prevalent successful mechanisms is via
lentiviral vector mediated gene delivery. Although most work has been done in lentivirus, other
viral vector systems exist and each presents its own advantages and limitations (Figure 13).

Figure 13. Viral vectors used in gene therapy.
Vectors have been derived from a number of viral systems including Retrovirus, Herpesvirus,
Adenovirus, and Adeno-Associated Virus. Table provides key characteristics and properties of
each system. (Adapted from Kalburgi, et al. Discovery medicine 15.81 (2013): 111-119.)
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For example, while Adenovirus can hold up to 36kb of DNA, it is only suitable for therapies that
require transient expression, as the virus is non-integrating93. Adeno-Associated Virus (AAV)
provides stable expression, but is limited in terms of the amount of exogenous DNA able to be
packaged into the vector94. Retroviruses have been utilized for CAR T cell therapy as well as for
targeting dendritic cells95, but rely on a mitotically dividing population for gene delivery. On the
other hand, lentiviral particles have the ability to infect both dividing and non-dividing
populations, and have been extensively modified for safety and efficacy96. Here, we specifically
discuss lentiviral vectors for their ability to transduce non-dividing hematopoietic stem cells in a
therapeutic setting.

4.2 Lentiviral gene components and vector structure

HIV-1 is a single-stranded RNA lentivirus. Upon reverse transcription, the viral DNA can be
integrated into the host genome. The HIV-1 genome contains 9 genes which span over ~9kb and
encode a variety of structural, regulatory and accessory proteins. Flanking the viral coding
regions are cis regulatory elements such as long terminal repeats (LTR), a packaging signal (Ψ)
and a rev response element (RRE).

Gag and pol are translated into precursor proteins, which give rise to the core structural and
transcriptional proteins of the virus. Proteolytic cleavage of Pol yields proteins PR (protease), RT
(reverse transcriptase) and IN (integrase). The protease activity of PR is responsible for the
processing of both Pol and Gag into their final products. RT reverse transcribes the viral RNA
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genome into DNA for integration into the host genome by IN. Gag precursor is further processed
into matrix

10

, capsid (CA), nucleocapsid (NC) and p6 proteins, which are essential for the

formation and infrastructure of the virion as well as post-entry and viral release steps.

Envelope glycoprotein (env) also encodes a precursor protein (gp160) which is proteolytically
cleaved into two surface proteins: gp120 and gp41. Both are essential for effective host-receptor
binding. In particular, gp120 mediates the binding to the CD4 receptors on T cells and
macrophages97. Upon binding and attachment, the host cell membrane fuses with the viral
membrane, and viral entry is facilitated via gp4197.

Transactivator (Tat) and Rev are involved in the enhancement and regulation of transcription.
Flanking the viral genome on the 5’ and 3’ ends are Long Terminal Repeats (LTR). Within LTR
regions exist promoter and enhancer sites that are essential for viral transcription. The LTR also
functions in viral integration into the host genome as well as polyadenylation of viral RNA.
LTRs alone, however, are inadequate for effective transcription and must work in conjunction
with Tat to promote production of viral transcripts (and ultimately proteins). Additionally, Rev
binds to the Rev-responsive element (RRE) to enable nuclear export of unspliced transcripts
required to produce some HIV gene products.

In addition to the genes that encode the structural and transcription-regulating proteins, HIV-1
possesses four accessory genes that improve viral infectivity. Accessory proteins act to degrade
host immune responses as well as to boost viral ability to invade and propagate within cells. The
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optimization of current lentiviral gene therapy strategies has allowed for the exclusion of these
genes from vectors. Efficacy and safety are improved in their absence.

Gene therapy is reliant upon the ability of the viral vector to enter and integrate into host cells.
The endogenous Env protein product, gp120 has specific affinity for CD4+ cells. The use of
gp120 to form the envelope can result in pathogenic consequences, and can also limit the
potential pool of patient cells that can be infected by gene therapy vectors. As such, heterologous
envelopes that allow for a greater diversity of host cell infection can be used. This is referred to
as pseudotyping. Vesicular stomatitis virus glycoprotein G (VSV-G) is now commonly used in
lentiviral gene therapy vectors. VSV-G is more stable than other retroviral envelopes and can
transduce a wider array of cells including HSCs, with high efficiency98.

In addition to altering vectors by pseudotyping to generate a more robust transduction, other
modifications must be made to ensure safety. As previously mentioned, the viral genome is
flanked by 5’ and 3’ LTRs, which contain strong enhancers. Upon transduction, a potential
consequence of random integration into the host genome is that LTRs may activate nearby genes,
including proto-oncogenes. Self-inactivating (SIN) vectors have been designed to reduce the
possible occurrence of vector-mediated oncogenesis. SIN vectors lack the U3 portion of the 3’
LTR, which results in an inactivation of transcription in viruses. Furthermore, viral genes are
delivered in separate vectors to decrease the probability of recombination that could result in
active HIV-1 viruses. In this system, required HIV genes for viral expression and envelope
assembly are placed into different vectors99,

100, 101

. A third transgene-bearing vector is also

introduced. Many vector systems have included central polypurine tract (cPPT) to increase
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transduction efficiency102 as well as Woodchuck hepatitis virus post-transcriptional regulatory
element (WPRE) for enhanced transgene expression103.
4.3 Use of LCR components in lentiviral gene therapy

Lentiviral vector gene therapy has proven a safe and efficacious gene transfer technology, and
has therefore been used in many successful clinical trials. Because of the SIN modifications that
rendered the vectors devoid of many of their own regulatory elements (LTR, promoter,
enhancer), lentivirus has gained favorability over retroviruses for decreased insertional
mutagenesis. Lentivirus still does, however, tend to favor genomic ‘hot spots’ along gene bodies
rather than the retrovirally-favored regulatory elements104. Due to their ability to integrate fairly
randomly within the genome, therapeutic genes delivered via these vectors require another level
of regulation to ensure predictable and innocuous gene expression patterns.

One of the first major steps towards the utilization of gene regulatory elements in gene therapy
was demonstrated in a mouse model of β-Thalassemia using the β-globin LCR30. In similar
fashion to the T cell receptor, β-globin expression is regulated by an LCR that spans 20kb in its
endogenous locus14, 105. Of the 5 DNase I hypersensitive sites that encompass the β-globin LCR,
some were functionally characterized, and portions of those were incorporated into lentiviral
vectors to assess whether they could restore β-globin levels to physiological levels. A ‘miniLCR’ containing ~1kb of three core HS sub-elements was first tested, and found to yield
insufficient β-globin expression, whereas incorporation of additional DNA sequence from these
HS enabled predicted LCR activity30.
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Elements of TCRα LCR in the context of gene delivery vectors could also be used to drive
predictable expression of therapeutic genes, or CARs in clinical settings. The precedent set by
the success in the β-globin field has paved the way for the use of regulatory elements, and the
characterization of TCRα mini LCR cassettes make their incorporation into viral vectors a
logical progression in translating these studies. Thus, lentiviral packaging and transfer vectors
were acquired from the Sadelain group at MSKCC, and modified by Dr. Armin Lahiji to include
the TαLCR4.0 or TαLCR 1.3 mini LCRs (Figure 14).

Figure 14. Lentiviral vectors for gene delivery.
pCMVR8.9101 includes Gag, Pol, Tat and Rev genes, which are required for viral packaging. The
pMD.G99 envelope vector encodes a pseudotyped VSV-G envelope protein, for wider cell
affinity. A transfer vector construct bearing a transgene linked to a mini-LCR is included in
vector flanked viral LTRs (SIN). This vector also encodes a transduction marker (NTP) as well
as elements that enhance transduction and transgene expression (cPPT, WPRE, respectively).
The transfer vector was constructed to include mini LCR constructs linked to a yellow
fluorescent protein (YFP) with a T-cell specific Vα promoter, that is detectable using flow
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cytometry. A modified Low Affinity Nerve Growth Factor Receptor (LNGFR) protein, or NTP
driven by a human phosphoglycerate kinase 1 (hPGK) promoter serves as a transduction marker,
as it traffics to the cell surface and can be tracked using flow cytometry as well. It was confirmed
that both NTP and YFP were expressed when vectors were transfected into a mature T cell line
(VL3-3M2), thus ensuring that the components of the LCR do not interfere with NTP expression
(Lahiji and Rist, unpublished data). Along with the transfer vector described above, two other
vectors containing the aforementioned essential viral elements (pCMVR8.9, pMD.G) can be
transfected into 293T cells and tested for packaging and transduction ability, as well as for the
ability to drive transgene expression in a TCRα-like manner.
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4.4 Transfection, transduction, and packaging of lentiviral particles

Figure 15. Overview of viral production assay.
Co-transfection of viral vectors into a packaging cell line (293T) allows for viral assembly, after
which they emerge from cells into supernatant, which is collected and concentrated. The
resulting virus-containing solution is used to transduce target cells, after which cells can be
analyzed for successful infection via flow cytometry.
In order to test whether the minimal elements of the TCRα LCR in the context of lentiviral
vectors could confer the predicted patterning of gene expression, the transfer vector, along with a
packaging vector, and envelope vector were co-transfected into HEK-293T cells. As a
transfection control, a sample transfected with a transfer vector containing only hPGK-GFP was
tested as well. 24 hours post-transfection, roughly 80% of cells should be GFP positive,
indicating DNA uptake by cells (cells viewed under fluorescent microscope and roughly scored
for GFP expression, data not shown). Transfection was optimized by testing Hepes-Buffered
Saline (HBS) with calcium chloride, Lipofectamine, or polyethylenimine (PEI) transfection
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methods. 48 hours post-transfection, viral particles should begin to emerge from cells, and viruscontaining media is collected. To concentrate the virus, two different methods were employed;
ultracentrifugation and polyethylene glycol (PEG) precipitation. The concentrated virus can then
be serially diluted and used to transduce other cells and to determine viral titers (Figure 15).

After optimizing transfection protocols to yield a high percentage of GFP positive cells, it
became evident that there existed either an inability of the virus to properly package, or to be
transduced. This was hypothesized after an experiment in which both a GFP control transfer
vector, as well as an LCR-bearing vector, were transfected, and concentrated media was used to
transduce 293T cells. Whereas there was signal in the control, the samples from cells transduced
with lentivirus containing mini LCRs were devoid of NTP expression (Figure 16).
Figure 16. Reporter expression
with increasing concentration of
virus in cells transduced with
control, and LCR-bearing lentiviral
vector.
(A). Control virus, containing only
GFP, produced signal that
increased when transduced with
increasing concentration of virus.
(B). With LCR-bearing vectors,
transduced cells failed to express
the NTP transduction marker,
regardless of viral concentration
used to transduce.
There are a number of elements within the mini LCR-containing transfer vector including the
mini LCR might not be amenable to these processes. Elements within the LCR sequence itself,
or other sequences unique to the LCR-containing vectors, such as the SV40 polyadenylation
sequence106,
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impacted viral production. There is data to suggest that viral packing is dependent upon the
secondary structures formed by the viral RNA108. These structures can be impacted by
incorporation of intronic, alternative splicing, or polyadenylation sequences within viral
vectors107,

109

. If, indeed, such inhibitory variables are present, viral production would be

impeded and might result in low titers. Therefore, in accordance with data published from the
Sadelain group, we sought to build new vectors with varying modifications to ensure the
production and transduction abilities of lentiviral particles made from these vectors. It has been
observed that YFP could be silenced through differentiation, potentially because of its genomic
configuration and non-mammalian origins (Lahiji, unpublished data). Thus, we first generated a
vector with a Vα-driven CAR (anti-CD19), which has not only been established as a gene that
can be expressed through differentiation in mammalian cells110, but has also been heavily utilized
in eight recent clinical trials for gene therapy111 (Figure 17B).
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Figure 17. Modified viral transfer vectors.
(A). Vector containing a mini LCR linked to a Vα-driven YFP transgene, along with human
PGK-driven NTP transduction marker. (B). To utilize a clinically relevant transgene that has
been established through the differentiation process as well as in clinical trials, a CAR-GFP
replaced the YFP transgene. (C). To test whether the polyA tail associated with the transgene
could improve viral production, an established bovine growth hormone polyA tail took the place
of the existing SV40 polyA.
Utilization of a CAR would render vectors more translationally relevant, especially if linking it
to the LCR could ameliorate some of the current limitations in gene silencing and variegated
expression patterns112. It has been shown that viral RNA production is impacted by orientation of
polyadenylation sequences associated with the gene106,

107

. The SV40 polyA of the YFP

transgene contains both sense and anti-sense polyadenylation sequences, corresponding to both
early and late polyadenyation signals. Indeed, the third AATAAA appears to be part of the
functional late SV40pA, which could result in decreased viral RNA production. The SV40 polyA
of YFP was therefore replaced with the bovine growth hormone (bGH) polyA tail, which has
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been utilized and established in lentiviral production113, 114 (Figure 17C). Alternatively, it is
possible that inhibitory sequences within the LCR itself exist, and interfere with lentiviral
packaging. In the case of the β-globin LCR, such sequences were mutagenized, resulting in
higher viral titers109. Many of the described inhibitory sequences that resided in the β-globin
LCR were also found in a scan of TCRα LCR constructs (Figure 18). As such, it is plausible that
LCR constructs might be refractory to viral RNA transcription, or packaging, resulting in very
low, or undetectable titers. Sites encoding reverse polyadenylation sequences, and splicing
signals, in which these sequences are found could be mutagenized, as was done in the case of the
β-globin LCR, to alleviate the inhibition that potentially could arise as their consequence.

Figure 18. DNA sequences within TCRα LCR that might result in viral instability and low titer.
Select A/T-rich regions, reverse polyadenylation signals and splice sites that were identified
within the β-globin LCR were mapped onto TCRα LCR sequences incorporated into lentiviral
vectors. These sequences might result in viral instability or low viral titers.
Thus, a set of new transfer vectors was made to accommodate for all of the possible iterations
that could impact packaging and production of lentivirus. The initial transfer vector (Lahiji
thesis, 2013) contained a Vα-driven YFP transgene linked to the mini LCR. To address the
potential inability for a YFP reporter to be (a) expressed in a mammalian system and (b) undergo
and be expressed through differentiation, it was replaced by an anti-CD19 CAR, generously
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provided by the Sadelain lab. Alternatively, the YFP might be amenable to the above conditions,
but might be negatively impacted by SV40 polyA sequences, which are shown to be refractory to
viral RNA transcription and packaging106, 107. A bGH polyA tail replaced the SV40, and was
linked to the mini LCR-YFP cassette. Each of the newly cloned constructs was tested in the viral
production assay. Following transfection, fluorescent microscopy was used to detect GFP/YFP.
Upon confirmation that the DNA had been taken up by cells, we chose to proceed using the PEG
precipitation to concentrate viral particles, from which we would make the dilutions for viral
titering. Various concentrations of virus were used to transduce, in 293T, 3T3, HeLa, and VL3
cell lines. In 293T and HeLa cells, we assessed for presence of the transduction marker, NTP,
using flow cytometry. We were unable to test for YFP expression since it is driven by a Vα
promoter, which is T cell specific. In the T cell line (VL3), however, we were able to look at
both NTP and YFP expression.

Along with the transduced cells, a non-transduced cell population was run through flow
cytometry as a negative control for the NTP marker. After gating on NTP, histograms for
transduced cells were overlayed with non-transduced cells. Dilutions ranged from 1:101:100,000, as well as a sample in which undiluted viral media was added to cells. Viruses
contained either GFP only (control), YFP-SV40pA, or YFP-bGHpA. Results from the
transductions seemed to yield a marked shift in NTP expression between non-transduced and
transduced cells, regardless of the dilutions (Figure 19). In order to confirm the FACS findings,
we visualized the cells using fluorescent microscopy with the help of the Feinstein and Bratu
Laboratories, Hunter College. The results of the cell imaging were consistent with the results of
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FACS, showing a majority of the cells appeared to be GFP or PE positive, though background
auto-fluorescence is suspected to have led to this appearance (data not shown).

We further sought to transduce a DP T cell line with the viruses in order to be able to visualize
YFP expression, since it is linked to a T cell specific promoter, and thus only expressed in T
cells. In cells transduced with undiluted virus of all the vector types, there was a positive signal
in the FITC channel, indicating YFP or GFP (from a positive control vector, pRRL GFP)
expression (Figure 19B). We also assessed for NTP expression, and found an increase in
expression in all samples of roughly equivalent amounts, including the negative control, which
contains no NTP (Figure 19A). Because the NTP-free control yielded a similar signal to that of
the experimental samples, the results were questionable, and any positive signal could be
attributed to high background.
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Figure 19.Transduction in VL3 double positive T cells to assess NTP and YFP expression.
Control vector, containing only GFP driven by hPGK promoter (pRRL GFP), as well as pRRL
SV40pA (containing a Vα promoter driving YFP containing an SV40pA linked to TαLCR4.0),
and pRRL bGHpA (containing a Vα promoter driving YFP containing an bGHpA linked to
TαLCR4.0) vectors were used to transduce VL3 cells, and were analyzed for NTP expression.
pRRL GFP, despite containing no NTP, produced a similar signal to that of pRRL SV40 polyA,
and pRRL bGH polyA in undiluted samples. (B). The same samples were assessed for YFP
expression, and pRRL GFP control, pRRL SV40, and pRRL bGH vectors produced similar
signals in both undiluted and diluted viral transduction.
In order to account for potential background signal coming from the experimental process and
reagents, we introduced two controls to experiments. Both controls were designed to eliminate
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any variable coming from reagents that might yield a positive signal. The first was a mock
transduction control, in which samples underwent mock transfection, concentration with PEG,
and transduction. In this way, any potential fluorescent signal emerging from reagents (PEG)
would be incorporated into the background, and only signal resulting from transduction would
yield a shift beyond that fluorescence. A second control included using the mock experimental
supernatant as the diluent for transduction. Whereas dilutions for viral titrations were initially
made using media, mock supernatant was now used to account for any differences in
fluorescence that might be produced by the reagents or procedural events, in attempt to
normalize results and yield accurate readings of transduction efficiency across varying dilutions.
Even with the newly controlled set of experiments, however, there was no change in background
levels. pRRL GFP, should not yield any signal at all in the PE channel, since it does not contain
the NTP transduction marker. The positive signal in the NTP channel of similar strength to that
of the GFP signal seemingly invalidate the result. Perhaps by transfecting more cells, and
producing more virus-containing supernatant, higher viral titers can be achieved such that the
positive signal will be distinguishable from that of the background. Once this is optimized, the
differences conferred by incorporating either SV40pA or bGHpA can be determined. Once tested
in cell lines, and viral titers are calculated, it will be possible to test viral vectors in HSCs derived
from mouse bone marrow, or in mESCs.
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Chapter 5: Beyond the bench: an Innovation Corps experience
5.1 The business of science: immuno-oncology and CAR-T treatment
	
  
The immuno-oncology (IO) field, at present, comprises a handful of dominant therapies, such as
vaccinations, monoclonal antibody, checkpoint inhibitor, and CAR-T therapies, among others.
Together, they constitute a vast and growing market, which is predicted to reach 100 billion
dollars by the year 2020 (Global & USA Cancer Immunotherapy Market Analysis to 2020
report). This space is occupied by a number of key players that span the academic and industry
spectrum. It is the synergy of high-quality, paradigm-shifting science, with ample resources that
continue the flow through the IO pipeline.

Figure 20. Clinical phase
distribution of IO assets.
While IO research can be
funded at any stage of the
clinical trial process, 63% of
projects are funded at the early
stage, involving more risk, but
more promise. This is
especially pertinent to research
emerging from academic
institutions.

Partnerships between academic institutions with ‘big pharma’ and emerging biotech companies
have become one of the leading models in generating hypothesis-driven clinical trials. Many
scientists are classically trained to design and execute experiments with no context of clinical
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trial development, and therefore require external expertise and capital to move discoveries to the
clinic. Partnerships or acquisitions can occur at different stages of project development, however
the IO space, in particular, many deals occur in early-stage technologies in the preclinical/research project phase (Evaluate Pharma, DH analysis) (Figure 22).

The advent and success of CAR T therapy has yielded unprecedented results in recent years. As
per a Cancer Research Institute database generated in September 2017 (Shalabi and Lucey
ESMO 2017), over 290 CAR T therapies were being developed, with over 160 of them being
tested in the clinic. CD19 has been a popular target, as it has proven effective in patients with
Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin’s Lymphoma (NHL), and Chronic
Lymphocytic leukemia (CLL)39, 115, 116, 117. In five trials, between 70-94% of patient participants
suffering from ALL or NHL achieved a “complete response”, or disappearance of all signs of
cancer in response to the treatment (National Cancer Institute) (clinical trials (NCT00968760,
NCT01865617, NCT01815749, NCT01626495, NCT01044069)44. The results for CAR T in
hematological malignancies are encouraging, likely owing to the accessibility of the liquid
tumors to the circulating CAR T cells. Thus far, the FDA has approved two CAR T cell based
therapies designed against B cell tumors; Kymriah (tisagenlecleucel, Novartis, 2017) and
Yescarta (axicabtagene ciloleucel, Kite Pharma, 2017), but other B cell antigens are being
targeted in other pre-clinical models in hopes of continued success. Efforts to generate therapies
that can target solid tumors have been met with more hurdles, some of which include T cell
homing to tumors, and tumor microenvironment. Other efforts to generate “off the shelf”
therapies (Cellectis, Celyad), which would utilize allogeneic cell sources seem feasible, but run a
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risk of graft-versus-host disease. This technology would, however, render the therapy much
cheaper, as it eliminates the requirement for individualized manufacturing.

Immunotherapy, as it stands at present, involves intricacies, costs, and challenges. Further
progress will necessitate the integration of biological and medical data, and efficient clinical
development. From the perspective of innovative trial design, strategies for evaluation, improved
tools and manufacturing capabilities, as well as exploiting big-data target mining, and creating
relevant pre-clinical humanized models that can inform trials are the next necessary steps. The
understanding of the underlying basic biology that governs the mechanisms of action will shape
the design and execution of safe, targeted, and effective gene therapy administration.

The basic biology of gene regulation, in particular, can be applied to address the current state and
limitations of immunotherapy. Specifically, the main obstacles to clinical benefit of these
therapies include the durability of the treatment, and associated toxicities. The durability of the
treatment might result from the exhaustion118 and/or loss of modified T populations over time, or
from the inactivation of the therapeutic gene via epigenetic silencing. Engineering stem cell
populations with therapeutic genes can give rise to a renewable source of T cells containing the
therapeutic gene product over the lifetime of the patient. However, stem cell populations, such as
HSCs can give rise to all blood cells, which can potentially result in therapeutic gene expression
in multiple cell lineages, and at unspecified developmental stages. While it has been suggested
that expression in earlier-derived cells, such as NK cells, can yield a “fast response” before T
cells emerge from HSCs119, ectopic expression of TCRs either in premature T cells42 or in non-T
cells41 has been shown to be deleterious, or lead to a block at early stages of T cell development,
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thus requiring tight spatiotemporal regulation from transduced cells. Moreover, equipping such a
wide array of cells with reactive potential, potentially beginning in lineages as early as stem cells
can result in an inflammatory environment, and intensify treatment-associated toxicities.
Additionally, subjecting a transgene to the dynamic chromatin landscape can lead to its
extinguished expression over the course of differentiation, even in the presence of constitutively
active promoters. Either loss of engineered T cells and silencing over differentiation can
diminish therapeutic benefit over time, and might necessitate another round of patient treatment.
At present, toxicities such as Cytokine Release Syndrome, which is characterized by elevated
levels of pro-inflammatory cytokines, interferon-γ, and macrophage activation39 can be treated
with corticosteroids, which can limit the efficacy of immunotherapy. CRS can be life-threatening
and must therefore be managed effectively; symptoms must be controlled without compromising
T cell activity. It was more recently reported that an IL-6 blockade could also be used without
significantly impacting therapeutic T cell function (CD19-Redirected Chimeric Antigen
Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of
Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6
Antagonist Tocilizumab (toc). Grupp, et.al.,	
  54th ASH Annual Meeting and Exposition; Atlanta,
GA. 2012.). It should be noted, however, that complete response (CR) rates of patients is
associated with degree of CRS.

Given the above parameters, it seems necessary to properly modulate and insulate the expression
of a therapeutic gene in space and time. Conferring a therapeutic gene, such as a Chimeric
Antigen Receptor, with the proper TCRα-like patterning can potentially restrict CAR expression
to T cell progeny of HSCs, in a high-level, predictable manner. Importantly, the ability to
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regulate a CAR in a natural TCRαβ-like manner can yield higher efficacy, or even reduce CARrelated toxicity, such as CRS. A study that examined the function of a CAR targeted to the TCR
locus, placing it under its endogenous regulatory elements, found that there was reduced tonic
signaling as well as reduced T cell exhaustion, but improved overall efficacy of CAR T cells120.
This highlights the importance of using cis elements, like the TCRα LCR, in order to provide a
more well-characterized and predictable therapeutic product. As demonstrated, mini LCR-driven
reporter genes are expressed in T cells regardless of their genomic integration site, at the correct
stage of development. Moreover, modulating therapeutic gene expression in physiological
TCRαβ-like fashion can reduce or prevent toxicities such as CRS altogether, eliminating the
need for additional drugs that might inhibit the initial therapeutic benefit. 	
  

5.2 CisTar: A novel gene regulatory platform for stem cell based therapies

The ability of the TCRα LCR to modulate the expression of a linked gene in a way that is
position independent, copy-number-related, and with the spatiotemporal specificity pattern of the
TCRα gene, makes its use in CAR T therapy seemingly appealing and suitable. The generation
of mini LCR cassettes that are able to recapitulate full LCR activity makes this system further
amenable to a gene therapy setting. The largest of the mini LCR constructs, TαLCR4.0, retains
TCRα-like expression patterns, even when reduced by ~70% of the full-length LCR. This
“downsizing” enables its use in the context of lentiviral gene delivery vectors. Linking this mini
LCR to a CAR would confer TCRα-like regulation, and could therefore add a layer of safety that
could prevent some of the side effects currently associated with uncontrolled, and unpredictable
regulation of therapeutic genes. Specifically, this linkage could prevent malignancies associated
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with ectopic expression of the engineered gene41 and also positively impact the duration of the
therapeutic response. Moreover, the even smaller TαLCR1.3, retains its ability to overcome
position effects, but confers only partial copy number dependence and is expressed in monocytes
(and perhaps other tissues that have not yet been tested). Nevertheless, this version of the mini
LCR can still be useful in other capacities, such as in HIV therapy, since HIV can infect both T
cells and monocytic populations121. There is evidence that suggests that is possible to make T
cells or monocytes resistant to infection by HIV by producing therapeutic siRNA122 or
proteins123 that disrupt HIV-co-receptor binding. Driving the T cell or monocyte-specific
expression of these gene products would be made possible by linking them to TαLCR1.3. Other
mini TCRα LCRs could potentially be constructed that would have varying specificities that
might render them appropriate to drive expression in other predictable patterns appropriate for
other T cell immunodeficiencies. Engineering T cells to express correct copies of otherwise
mutated genes can address T cell diseases such as SCID, which results from mutations in genes
(such as ADA, Jak3) that impact T cell development and function124. The ability of the LCR to
drive restricted spatiotemporal patterning of an associated gene can allow for its use in stem cell
based therapies to specify expression to a particular type(s) of progeny cells. This property can
enable a stable, renewable therapeutic source, which can reduce the need for reinfusion in
patients.

Given the current recognition of Chimeric Antigen Receptors in immunotherapy, as well as a
basic understanding of the gene regulatory landscape that modulates T-cell receptor expression,
it would be interesting to apply the scientific knowledge to a relevant clinical system. Harnessing
the ability to potentially remedy pitfalls in gene therapy would be useful to patients, physicians,
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and even commercial producers of gene therapy. As we recognize the commercial potential of
the study, we applied to the National Science Foundation (NSF) Innovation Corps (I-Corps)
program, with the goal of understanding the viability of the lab’s intellectual property (IP) to
launch a startup company. I-Corps is designed to help scientists assess and realize the
commercial feasibility of innovations emerging from their research by intensive training from
industry leaders as well as the ‘get out of the building’ method, in which interviews are
conducted with key opinion leaders (KOL) in the field. Further, the New York City Innovation
Node (NYCRIN) branch of I-Corps aims to enhance the biotech ecosystem in New York and the
surrounding regions by fostering a strong network for growth and development. Gayathri
Raghupathy and I assumed positions of entrepreneurial leads (ELs), with Dr. Ben Ortiz as
principal investigator, and Dr. Eric Vieira as our industry mentor. Based on Steve Blank’s Lean
Startup plan, which emphasizes evidence-based entrepreneurship, we constructed a testable
business hypothesis, and tracked our ‘data’ on a business canvas model. The business model
includes nine key channels that help entrepreneurs test the components of their central business
hypothesis, including customer segmentation, partners, resources, revenue streams, and value
proposition (Figure 23). Initially, the canvas was populated with a narrowly scoped technology
aimed only at clinicians, but evolved over the course of the I-Corps journey to use mini LCRs as
a platform technology, that can be multi-purposed and made-to-order for various disease
indications. This journey was mainly guided by our in-person customer interviews that informed
each change along the way.

	
  

59	
  

Figure 21. Business model canvas.
The business model canvas is segregated into nine channels, which are populated by
entrepreneurs to focus plans and customer interviews. The evolution of the canvas over I-Corps
reflects pivots and fine-tuning, emerging from discussions with potential customers. Channels
include Key Partners, Key Activities, Value Propositions, Customer Relationships, Customer
Segments, Key Resources, Channels, Cost Structure, and Revenue Streams.
What we discovered through interviewing 47 KOL was that the CAR T technology was faced
with some main challenges: (1) Safety, (2) Ability to prepare a ‘universal donor’, (3) Cost and
efficiency, (4) Expansion to a wider set of indications and targets (solid tumors, etc.), and (5)
Overcoming the tumor-suppressive microenvironment. The mini LCR platform could address
some of the current challenges, and help progress the field of gene therapy.

Along the lines of safety, there have been major toxicities associated with the therapy that have
caused substantial hurdles to FDA approval and use in the clinic. The two main concerns are
associated with on-target, off-tumor effects, and cytokine storms. On-target, off-tumor effects
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can occur when the CAR is driven to an antigen that is not exclusive to the cancer cell. For
example, the highly popular anti-CD19 CAR has been shown to result in B cell aplasia in
patients115 116, as well as the anti-ERBB2 CAR that targets her2, which can be expressed in nontumor tissues such as heart and lung125. The identification of more specific targets that are
restricted to tumor tissue is therefore being highly prioritized in the field. Cytokine storms refer
to the “immune Armageddon” that cause high fevers, hypotension, and potentially even organ
failure in patients receiving T cell therapies. These side effects are thought to be caused by the
high number of activated T cells infused into the patient39, 115, 126 as well as high tumor burdens.

So far, the data regarding T cell persistence is highly variable, ranging from weeks to years.
Ideally, a balance can be achieved such that safety is uncompromised by longevity of engineered
T cells, but that patients do not need to be re-infused with therapeutic cells numerous times, as
this negatively impacts both cost and efficiency of treatment. Since the LCR has shown to
possess the ability to restrict linked gene expression to T cells, if a construct were to be
introduced to a hematopoietic stem cell population, therapeutic gene expression should be
limited to only T cell progeny of HSCs. This would provide a renewable pool for the treatment,
and potentially avoid the necessity for re-infusion. Additionally, the LCR has the ability to
regulate two flanking genes at the same time, in the context of a BAC127. A “suicide gene” can
also be linked to the LCR to enable the ability to mediate discontinuous therapy, which can
prevent excessive cytokine release, via intermittent activation of drug-induced apoptosis in
engineered T cells128. The suicide gene most classically tested in humans is the Herpes Simplex
Virus- derived thymidine kinase (TK) gene, wherein upon administration of Ganciclovir, cells
expressing this gene are killed129. Linking TK to the TCRαLCR could enable its expression in T
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cells, but not in HSC reservoirs, thus eliminating active cells while preserving their stem cell
source. Implementation of this system, wherein a mini TCRα LCR construct linked to both a
therapeutic and a suicide gene can be transduced into HSCs, but only expressed in T cells
emerging from the renewable stem cell pool, might limit side effects associated with treatment.
Upon administration of TK, only actively expressing T cells will be eliminated, without
destroying the therapeutic source. Alternatively, methods have been explored in which cells
permanently express individual CAR components in a “split CAR design”, which do not activate
until a small molecular enables dimerization130. This can also impose a layer of control that can
help mitigate excessive T cell activity resulting in toxicity.

There exists documentation of insertional mutagenesis resulting in malignancy in patients who
received retrovirally-transduced HSC transplants, which caused concern about the safety of such
treatments. While insertional mutagenesis has been documented when virally-transducing
hematopoietic stem cell populations131, there are ways that are currently being employed to
bypass this threat. Initial retroviral gene therapy trials in HSCs to treat Severe Combined
Immunodeficiency (SCID) favored insertion within the LMO2 locus, a known oncogene, leading
to tumorogenesis132. Selectively incorporating genes into “safe harbor” sites134, however, can
achieve stable, long-term expression while preventing insertional mutagenesis. Safe harbors are
chosen to ensure that an inserted transgene will function and not interfere with, or be interfered
by, neighboring genes and elements, thereby reducing potential inappropriate regulatory crosstalk or gene-disruption. In order to attain a larger pool of a potentially renewable source of cells,
it is possible to derive patient-specific cells and induce regression into a stem cell- like lineage,
resulting in cells called induced pluripotent stem cells (iPSCs). In the case of iPSC technology,
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clones may be selected on the basis of possessing these characteristics, and theoretically
expanded and re-infused into the patient accordingly. While iPSC technology is promising, it is
not yet been approved in clinical immunotherapy models. Although we viewed insertional
mutagenesis as a significant hurdle going into I-Corps, our discussions with leaders in the field
of gene therapy helped us understand that this was not viewed as big of an impediment as we
suspected, given that current therapy models (using T cells) have no evidence of insertional
mutagenesis.

Conducting interviews with clinicians and scientists in both industry and in academia helped us
reshape our views of what some of the unmet needs in the field were, and how mini TCRα LCR
technology could potentially close the gaps. Mini LCRs can potentially mitigate some of the
safety risks observed by a number of current therapies. Limiting expression to T cells beginning
at the correct developmental stage, as well as potentially incorporating intermittent treatment via
suicide genes are some ways to increase the safety. Additionally, using HSCs provides
renewable sinks of cells that can prevent necessity for re-infusion, maximizing efficiency and
minimizing costs associated with production of GMP-quality cells for introduction to the patient.
We used this guidance to steer our business model to fill the gaps in the market.

5.3 Pivot! A business model for LCR-based therapies

Our hypothesis was built upon the business model canvas that we generated to outline the main
parameters that we needed to understand in order to commercialize our technology. The initial
value proposition (VP) that we offered was a regulatory element that could offer predictable gene
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expression that can overcome therapeutic gene silencing and reduce the toxicity associated with
current treatment plans (see above discussion on CRS). The channels through which we could
bring this to market were through scientists (in academia or industry), clinicians, biotech
companies, or via research tool companies. With key resources such as IP, academic and
industry collaborations along with the expertise in construct generation and assays; we focused
as a research and development endeavor, aiming toward product optimization toward clinical
trials. Additionally, we considered multiple revenue models; we could function as a start-up,
partner with leading companies to access their technology and clinical trial know-how, or even
license our science for royalties, milestone, or upfront payments. Given that we are a very earlystage enterprise, it would be advantageous to gain access to resources/funding in a research
sponsorship partnership. Partners could be academic, which would enable rapid deal structuring,
with individuals who speak our language. These institutions, however, do not always facilitate
commercialization and industry connections, nor do they always have the ability to fully carry
out clinical trials. Alternatively, partnering with big pharma might allow for more rapid
progression through trials with access to commercial operations. Partnering with industry players
might necessitate more advanced pre-clinical data, and they might therefore prefer a less
expensive early buy-out. Ultimately, the business plan is contingent upon the end customer. We
aimed to primarily cater to CAR T scientists as our major customer segment (CS). What we
learned, though, in customer interviews, was that our VPs did not necessarily match the pain
points in the field. Whereas we believed there was a demand for ways to solve issues such as
gene silencing, longevity, and toxicities, our customers pointed out that the current model of T
cell gene therapy already had protocols in place that are being tweaked. For example, clones can
be selected for favorable integration site, or, alternatively genes can be targeted into desirable
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loci for more predictable expression120. Abrogating toxicities associated with CRS has been
attempted utilizing management with other drugs (i.e. corticosteroids, cytokine-targeting), and
studying its causes on a basic scientific level135, 136. To work with a different model, such as stem
cell therapy, would create twists in the road to approval, even though it might be a better system.
If we wanted to shift the current model, we needed more pre-clinical data, such as more in vitro
data to validate what we have seen, as well as in vivo data in animals, and ultimately in humans,
to justify it. The ability of mini LCRs to recapitulate hallmark LCR properties across all models
to drive predictable and specific gene expression would be necessary in order to bring this closer
to patient populations. We targeted a new customer segment, scientists in the biotech industry,
who would be able to move the technology forward at a faster pace and offer efficient testing
platforms, both in CAR T and stem cell-based therapy spaces. The two major pivots we
experienced in VP (CAR T versus stem cell based therapy) and CS (academic to industry based
scientists) gave us a broader scope of how to navigate the commercialization of science. It gave
us the tools to see our technology through many lenses, and provided the opportunity to think
about data in a new light. We needed more solid pre-clinical (animal studies) and clinical data
(human studies) before moving more aggressively into the biotech space.

5.4 Reshaping the trajectory: scientists in a new space

I-Corps was a very significant player in shaping the way the research emerging from our lab
could be understood and applied, particularly within the IO space. “Getting out of the lab” forced
us to put our data and ideas into a wider context, and helped guide the thinking process governed
by the interplay of science and business. Increasingly, academic labs are funded by non-
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traditional grants, often from the private sector. Speaking with leaders in science and medicine
helped us identify the pain-points of the field, notably, the treatment of CRS, and improved
targeting of CARs. This gave us a better understanding of how TCRα LCR can address the
perceived limitations, in its ability to specify expression of linked genes to unique populations of
cells in a predictable and directed manner. It is imperative to have the foresight to and wide
scope to shape the scientific endpoint in a data-driven manner that is fitting for the current state
of the field. We learned to move with the data, be open to pivots and shifts, and to most
importantly let the science guide us.

This training, in conjunction with formal in-lab instruction has yielded a more complete, holistic
understanding of science. Speaking the language of biology as well as business is invaluable.
The ability to translate science to a wide spectrum of individuals makes data more relevant,
tangible, and far-reaching.

Chapter 6: Conclusions and future directions
	
  
	
  
The data presented here offer insight into the potential inner-workings of the TCRα LCR. Based
on the impact of progressive deletions in mini LCR constructs, we can narrow down some of the
properties associated with the sub-regions of HS. TαLCR4.0, despite containing only four of the
nine HS, seemingly retains the ability to drive spatiotemporally restricted expression of a linked
transgene in a copy number dependent manner. Based on this construct, as well as data from
years of characterization of HS1, HS1’, HS4, and HS6, these HS are sufficient for hallmark LCR
qualities. The generation of TαLCR2.9, introduced a deletion of HS4, and enabled us to delve
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more deeply into HS4’s contributions function in the context of the other HS. The lymphoidspecific hypomethylation47 and enrichment for acetylation marks137 of HS4 indicate an open
chromatin structure in T cells. This conformation might be associated with the decrease in
transgene expression and variegation phenotype in mice with HS4 deletions28. Interestingly, in
the two clones tested, while the spatiotemporal restriction of transgene expression was retained,
in mature T cells, a bimodal pattern was observed, corroborating with the in vivo data of lowerlevel transgene expression. The inability of the LCR to drive high-level expression in the
absence of HS4 can be attributed to possible position effects at the local chromatin site.

The incorporation of an evolutionarily conserved human homology block found in HS4 appears
to rescue the variegating expression of TαLCR2.9 in preliminary data from two independent
clones. TαLCR3.0 drives robust expression of the LCR-linked transgene at the mature DP stage
of T cell development. This expression is not activated at the early DN1 stage, nor is it switched
on in other lineages tested. Preliminary data from early (DN1) and Later (DP) T cells suggests
that the homology block might restore expression patterns to those seen in TαLCR4.0, which
might be attributed to some of the factors that are predicted to bind within the conserved
sequence. Among these are members of the Ets and RUNT protein families, which have been
implicated in chromatin modulation functions86, 87. Also predicted to bind to this region, in silico,
are GATA proteins, which are key regulators of hematopoietic development138. GATA motifs
have also been identified in the core HS of the β-globin LCR, and have been attributed as some
of the key motifs in establishing position independence in that locus139. These proteins, if bound,
along with others likely help mediate the suppression of position effects, and help recover the
loss of high- level gene expression seen in TαLCR2.9.
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Further reduction of the mini LCR in the TαLCR1.3 cassette was endeavored by eliminating
DNA 3’ to CTCF sites in HS1’ as well as DNA residing external to TF123 and HS316 motifs in
HS6. Early stage (DN1) T cells emerging from differentiated ES cells transfected with
TαLCR1.3 display premature activation kinetics, relative to the expected upregulation at the
DN3-DP transition. This upregulation is also seen ectopically, in monocytes derived from these
cultures. The resulting phenotype could be the product of the deletions made in either HS1’,
HS6, or both. HS1’ is responsible for the spatiotemporal control of both distribution of LCRdriven gene expression, as well as for the chromatin-opening ability of HS626. This ability of
HS6 speaks to its role in suppressing position effects. In particular, TF123 contains factorbinding sites that were identified in thymus, and the HS316 region support a more widespread
chromatin-opening ability27. The factor occupancy in HS6, however, is dictated by the presence
of HS1’27. These data taken together suggest an interplay between HS1’ and HS6. It is plausible
that some of this cross-talk is mediated by the missing regions in HS1’ or HS6. Despite inclusion
of CTCF binding sites in HS1’, which have been shown to mediate enhancer-blocking
insulation137, but are dispensable for overall LCR activity28, promiscuous gene expression might
be enabled by the absence of the 3’-most portion of this HS. The ~300bp of HS1’ DNA might
play a role in either enabling factor occupancy at HS6, or by allowing for physical interaction of
the two sites. Loss of transcription factor binding at either HS1’ or HS6 could therefore
potentially alter the epigenetic or physical landscape of the LCR. This is especially conceivable
since CTCF has been shown to form the 3D architecture in other loci (such as β-globin140, and
MHC class II141) to establish stage and tissue specificity. CTCF’s role in organizing the
landscape of the genome is often accomplished through physical interaction, which can be
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mediated by looping with itself, or in concert with other factors, such as cohesin142. Cohesin has
been found at HS1’137, and has also been shown to bind in the HS2-6 region of the LCR143.
Deletion of cohesion altered TCR rearrangement143 Jα transcription, which resulted in loss of an
activating epigenetic mark144, both impacting T cell development. Its role in the TCRα/Dad1
locus, however, with respect to how it might facilitate tissue specific enhancer blocking remains
unknown. A disruption of looping from loss of physical factor contact, or lack of recruitment
could result from deletion of sub regions in this construct.

Additionally, other factors might contribute to the loss of activity in TαLCR1.3. Using publicly
available ChIP-seq databases, as well as factor binding prediction databases, we identified a
range of factors that might bind to the 3’ end of HS1’ and the regions outside of TF123 and
HS316 in HS6 (Figure 22).

Figure 22. Predicted factor binding at HS1’ and HS6.
Using
transcription
factor
binding
site
prediction
software
(http://generegulation.com/pub/programs/alibaba2/), selected factors were mapped onto regions of deleted
HS sub-regions. Selected proteins were chosen based on their roles in chromatin modulation, or
immune function.

	
  

69	
  

Among these are factors that are known for their roles in chromatin modulation. FoxA1 has
binding sites in the probed regions of HS6, and has been shown to modulate chromatin via
nucleosome positioning, and has been shown to act as a pioneer factor in development145, 146.
Ets1 also has binding motifs within regions of HS6 excluded from the mini LCR. Ets1 has been
associated with transcriptional regulation in hematopoietic cells, and can bind directly to DNA,
or two other factors such as p300 (bound to HS4) to mediate its function147. SP1 and Oct1 are
well known for their roles in chromatin modulation, which can be exerted independently or
synergistically148, 149. Predicted binding sites for both of these factors are found along the probed
regions of HS1’ and HS6. These factors and others can impact the distribution of both proteins
and chromatin modifications along the body of the LCR, thereby directly influencing its function
(Figure 23).

Figure 23. Model of sub-region interactions.
Dark blue boxes indicate regions excluded from TaLCR1.3. We hypothesize that inter-play
amongst these is necessary to fully recapitulate LCR activity. The 300bp region in the 3’ end of
HS1’ might be responsible for the recruitment and binding of factors that help HS6 protect
against position effect variegation. Additionally, the HS4 homology block seemingly restores the
ability of the LCR to drive high-level transgene expression to the robust levels seen in the
presence of the complete HS4.
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Although robust, high-level expression is observed, it does fall out of the accepted range of strict
copy-number dependence. As suggested earlier, the absence of HS4 could result in subjectivity
to position effects, which might be manifest either by a decrease in transgene expression, or by
loss of copy number dependence.

The reestablishment of classical LCR activity could potentially be restored via the incorporation
of either of the two missing elements in TαLCR1.3 (within HS1’ or HS6). Two “rescue”
constructs were generated that reincorporate either one of these sub-regions: TαLCR1.6 restores
the 3’ end of HS1’, while TαLCR2.6 contains the full HS6, rather than just TF123 and HS316.
These constructs have already been transfected into ESCs, selected, and screened. Differentiation
of the mini LCR bearing ESCs followed by analysis of reporter expression would yield powerful
information on very narrow regions of the TCRα LCR, which would provide insight into
possible mechanisms of action.

Mini TCRα LCR technology would potentially offer an additional layer of specificity and safety
to existing T cell gene therapy approaches. As the constructs stand at present, even the largest of
the mini LCRs, at 4kb, would be amenable to insertion with a CAR into a gene delivery vector.
With the deeper analysis of the LCR sub-regions, it is possible not only to further reduce the
included HS, but to tailor the targeting to alternative cellular subsets, lineages, and disease
indications. While lentiviral vectors are a traditional gene delivery vehicle, efforts to test mini
TCRα LCR cassettes in their context require further investigation and optimization. We sought
here to remedy the potential pitfalls resulting from inhibitory polyadenylation sequences, and
attempted to render vectors more translatable and clinically relevant by using an established
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CAR that has undergone the viral production assays followed by cell differentiation. It is
possible that other variables might exist that are refractory to viral packaging and production in
this circumstance. Lentiviruses, although conventional, are now being cited for their ability to
stimulate adaptive and innate immune responses in recipients150. Alternative methods of gene
therapy, such as electroporation, lipofection151, transposition133, 152, and CRISPR120, 153, are now
more widely tested and accepted. Additionally, the advent of the aforementioned technologies
might enable more efficient therapeutic administration along with precise targeting, and
predictable, robust expression. It would be interesting to utilize novel methods along with mini
LCR technology to help advance the state of gene therapy.

Chapter 7: Materials and methods
7.1 Reporter gene constructs
	
  
	
  
hCD2ΔT84 is used as a reporter gene for all described constructs, and was excised from pBSK
SK using Sal I and Bam HI. hCD2ΔT was linked to the full TCRα LCR, excised using Kpn I and
Not I, and used as a positive control for experiments. To generate mini LCR constructs, various
sub-regions derived from pLCRc were incorporated as described below. TαLCR4.0 contains
HS1, HS1’, HS4, and HS6. PCR was used to generate the 1-kb HS1-1’ fragment, which is
defined by its Pvu II (in HS1) to BamH I (in HS1’) borders. An ApaL I – Dra I HS4 fragment as
well as an Mfe I - Ecl36 II fragment corresponding to HS6 were ligated to the HS1-1’ elements
to complete the TαLCR4.0. TαLCR2.9 was created by incorporation of the aforementioned
segments of HS1-1’ and HS6. TαLCR3.0 was made by incorporating an HS4 homology block
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(Figure 11) into TαLCR2.9 vector. The HS1-1’ fragment used in TαLCR1.3 incorporates a
~750bp region spanning from Pvu II – Sca I, as well as a 554-bp region of HS6 spanning from
Bcl I to Bgl II. TαLCR1.6 was generated using In-Fusion cloning technology (Clonetech) by
using PCR to yield the Pvu II- BamH I fragment corresponding to the full HS1-1’ sites and the
554-bp Bcl I- Bgl II fragment of HS6. These elements were incorporated into a pBSK vector
containing hCD2ΔT.

7.2 ESC culture and transfection

The murine ESC line, ESR1, are cultured in DMEM (Cellgro) supplemented with 20% ESCqualified FBS (Gemini), 1% Glutagro (Cellgro), 1% penicillin/ streptomycin (Cellgro), 1%
HEPES (Millipore), 1% nonessential amino acids (Millipore), 0.1% gentamicin (Life
Technologies), 0.1% β-mercaptoethanol (Life Technologies), and 10 ng/ml LIF (Millipore).
ESCs are grown on a mitomycin-C treated mouse embryonic fibroblast (Millipore) monolayer.
Transfection was done via electroporation (Bio-Rad gene pulser) at 0.24 kV and 500 µF. 7-12ng
of all constructs were individually transfected along with equimolar ratios of a 1.6-kb SV40driven neomycin resistance cassette derived from pEYFP-C1 (Clonetech) using Ssp I and
EcoO109 I. Cells were allowed to recover for 24 hours post transfection, whereupon selection
was carried out at 0.18mg/ml for approximately 10 days, when individual ESC colonies were
picked. Colonies were expanded and propagated under selection.

Screening for positive clones was done by both PCR and Southern Blot analysis. PCR primers
were designed in the hCD2 promoter (F: 5’-GAGGAAACCAACCCCTAAGATGAG-3’; R: 5’-
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CGTAATCTCTTTGGAGACTGCACC-3’). DNA from individual clones bearing a positive
PCR signal for hCD2 was digested using Bgl II for Southern Blot analysis to assess for
truncations and number of integrants. An 800-bp Bgl II probe was designed to bind to the HS6
region, as described in Harrow, et. al. 2005. Three sets of Southern Blots were done to confirm
copy number, which was normalized to the endogenous signal from the respective clone. The
probe design enabled detection of signal from both the endogenous TCRα locus as well as from
the transgene such that normalization for relative copy number could be done from a single blot.

7.3 ESC differentiation assay

ESC differentiation to T cells, and other hematopoietic lineages (such as erythroid and
monocytic) was done as previously described76, 154. Briefly, ESCs were plated onto an OP9-GFP
bone marrow stromal cell line for five days, after which the emrging blood mesoderm is cultured
along with Flt-3L (R&D Biosytems). Development progresses towards hematopoietic stem cells,
which are harvested and distributed onto either OP9-GFP for derivation of erythrocytes or
monocytes, or onto OP9-DL1s to drive T cell differentiation. Each co-culture was conducted
with individual mini-LCR clones along with a non-transfected ESR1 negative clone.
Additionally, a single copy clone bearing the full LCR was run as a positive control.

7.4 Flow Cytometry

Acquisition was done using the FACS Scan device. Harvested cells were Fc-blocked using anti
CD16/32 Ab (BD Biosciences), and stained with Abs as described below. Following 20 minutes
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of staining, samples were washed 3 times. On Day 12 of co-culture, the staining panel was
designed to detect early stage T cells, erythroid cells, and monocytic cells. Day 16 and Day 20
FACS detected later stage double negative as well as double positive and CD8 single positive T
cells. FITC conjugated anti-hCD2 (clone S5.2) was used for transgene detection. Dead Cell
Discriminator (DCD), or 7-AAD labeled dead cells. APC conjugated anti-CD45 (clone 30-F11),
AF-700-conjugated anti- CD44 (clone IM7), PE-conjugated anti-CD25 (clone 3C7), PE
conjugated anti-CD8 (clone 53-6.7), and AF-700-conjugated Ter119 (clone TER119) all from
BD Biosciences, and AF-700-conjugated to CD4, and PE-conjugated CD11b

(Life

Technologies) were used at appropriate FACS time points.

Analyses were done using FlowJo software (Tree Star). Forward and side scatter plots were used
to gate for lymphocyte populations, after which cells were further gated for negative DCD signal.
CD45 was used to gate for hematopoetically derived lineages (except for erythrocytes, which are
negative for CD45) in conjunction with appropriate aforementioned cell-type-specific markers.

7.5 qRT-PCR

Total RNA was collected from cells using Qiagen RNeasy micro kit, from which cDNA was
synthesized (NEB Protoscript cDNA Synthesis kit). qRT-PCR was done using Dynamo SYBR
Green qPCR kit (Thermo Fisher) on samples derived from a single well of a six well plate on
Day 20 of co-culture in an Applied-Biosystems Viia7 Real-Time PCR machine. To calculate the
mRNA levels, a non-transfected ESR1 was used as a calibrator, and TCRα was used as a
reference gene. The cycle threshold (Ct) values obtained using hCD2 primers (F: 5’-
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CCTTTCTGCTGGTGAACTTGTG-3’; R: 5’- TCAACACAACCCTGACCTGTG-3’), were
subtracted

from

the

Ct

value

calculated

from

the

TCRα

primers

(F:

5’-

AAGATCCTCGGTGTCAGGACA-3’; R: 5’- AGCAACCTTCCTCACAAATCTG-3’) to yield
the normalized ΔCt value per clone. Each ΔCt value was then subtracted by ESR1 calibrator to
determine the ΔΔCt. This value resulted in the normalized relative hCD2 expression level per
clone, as calculated using the 2-ΔΔCt method. Expression levels per copy were then obtained by
dividing by transgene copy number (Southern Blot) for each clone. Experiments were done in
triplicates. Relative fold difference was assigned by designating the clone with the highest
expression level as 1.0, and dividing the expression from individual clones.

7.6 Viral packaging constructs

To generate new transfer vectors for viral packaging, we began with an established vector
containing an anti-CD19 CAR driving a GFP transgene. The SV40 polyA tail was synthesized
using PCR (primers: F: 5’-GCGTCGACGCTTAAGATACATTGATGA-3’ R:
5’AAGCTCGAGGATCCACCGGATCTA3’), and cloned into the Sal I- Xho I sites in the parent
vector. This vector was cut using Age I- Nco I to insert the Vα promoter (F: 5’AAACCGGTAAGGACGGTAGCATTTTC-3’ R: 5’-GGCCATGGACCGGGAGATGTATTC3’) upstream of the CAR. The resulting Vα-CAR GFP-polyA cassette was excised using Bgl II
(blunted)- Xho and inserted into pBSK cut with Sal I (blunted)- XhoI. pgkNTP transduction
marker was liberated from the initial transfer vector using Sal I (blunted)- Xho I, and inserted
into the EcoR I- Sma I site in the new vector, to yield a full transcription unit containing VαCAR-GFP-polyA with pgkNTP in the opposite orientation. Using InFusion cloning technology
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(Clonetech), we used PCR to pick up the entire transcription unit (F: 5’GAGGTTGATTGTCGACGCGGTGGCGG3-’ R: 5’CTCGAGAAGCTTGATTACCGGGCCCC3-’) and place it into a new third generation lentiviral
backbone (Trono lab, purchased from Addgene) to yield the control vector. Primers were
designed to amplify either TαLCR4.0 (F: 5’-CCGGTGGATCCTCGACTCGAGCTGCA-3’ R:
5’-CGGGCCCCCCCTCGAGCGGCGGCCG-3’) or TαLCR1.3 (F: 5’CCGGTGGATCCTCGACTCGAGCTGCA-3’ R: 5’CGGGCCCCCCCTCGAGTACCGCGGCG-3’) for insertion into the Abs I site of pRRLtranscription unit vector. After sequencing analysis, a mutation in the Abs I site was identified,
such that the LCR could not be placed into the vector. Experiments with the control vector,
however, did not yield detectable NTP expression.

The original LCR-containing vectors (pRRL-LCR, Lahiji thesis, 2013) were manipulated to
incorporate the bGH polyA in place of the existing SV40 polyA. A G-block fragment (IDT) was
synthesized and contained the entire sequence for bGH polyA with PspX I ends (5’TGTACAAATTTCAGGGTGCAGCTCGAGCCATGCCTGCTATTGTCTTCCCAATCCTCCC
CCTTGCTGTCCTGCCCCACCCCACCCCCCAGAATAGAATGACACCTACTCAGACAAT
GCGATGCAATTTCCTCATTTTATTAGGAAAGGACAGTGGGAGTGGCACCTTCCAGGG
TCAAGGAAGGCACGGGGGAGGGGCAAACAACAGACGGCTGGCAACTAGAAGGCAC
AGTCGATCCCACTTGTACAGTCGATCCCACTTGTACAGTCGAGCTGCTGGGAC-3’ ) to
be restricted with PspX I and inserted into vector linearized with PspX I. Linearizing the pRRLLCR with PspX I removes a portion of pgkNTP, which was restored by priming up the fragment
from pRRL-LCR (F: 5’-CTGAAATCTTGTACAGCTCGTCCATGCC-3’ R: 5’-
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GAACACGAGGCTCGAGCCCGAGCCCGC-3’) and inserting it into the pRRL-bGH plasmid
linearized with PspX I.
7.7 Viral production assay

Viral production was done using protocols from Sadelain Lab, MSKCC. Prior to transfection,
293T cells were split such 80-90% confluence is achieved. 293T media (DMEM [Cellgro], 10%
FBS [Gemini], 1% Glutagro [Cellgro], 1% Penicillin/Streptomycin [Cellgro]) is replaced one
hour prior to transfection. A DNA mastermix is made using 10µg transfer vector, 7.5µg
CMVΔR8.91 (encodes gag, pol, tat, rev), 2.5µg pUCMDG (encodes VSV.G envelope), 50µl
CaCl2, up to 500µl with sterile dH2O per sample. For every 1mL of DNA mastermix, 1mL of 2X
Hepes Buffered Saline (5M NaCl, 1M Hepes [Cellgro], 1mM Na2HPO4, up to 500mL with
sterile dH2O, pH 7.12) is added dropwise, while vortexing. Then, 1mL of the mixture is added
dropwise to each 10cm dish. 16 hours post-transfection, media is replaced, and 24 hours after the
media change is the first collection of viral supernatant (a second collection can be done 24 hours
later). As an alternative to HBS/CaCl2 mediated transfection, Polyethylenimine (PEI,
Polysciences, Inc.) can be done. The same ratios of viral vectors as above are mixed to create a
DNA mastermix, along with 2mL of DMEM (Cellgro) and 70µl PEI.

Media is collected 48 hours post-transfection, and can be stored at 4°C. Collected supernatant
can be concentrated via ultracentrifugation (20,000rpm, 30 minutes, 4°C), or via polyethylene
glycol (PEG) precipitation (Systems Biosciences), following provided protocol. Briefly, this
entails adding 1 volume of PEG for every 4 volumes of viral supernatant, and refrigerating it at
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4°C overnight. After spinning at 4°C for 30 minutes at 1,500rpm, a white pellet will be visible,
and can be resuspended using PBS, aliquoted, and stored at -80°C.

Transduction can be done with or without polybrene. From our experience, even small amounts
of polybrene (ranging from 2-8µg) resulted in cell death relative to polybrene-free controls.
Dilutions in media can be made to titrate virus in multiple wells of a 6-well plate. After 24 hours,
media is changed, and cells can be passed, or analyzed via flow cytometry for NTP expression
(BD, clone C40-1457) or YFP.
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List of Abbreviations:

	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
  

1. TCRα: T-cell Receptor α
2. LCR: Locus Control Region
3. HS: Hypersensitive Site
4. Dad1: Defender Against Death 1
5. CAR: Chimeric Antigen Receptor
6. ESC: Embryonic Stem Cell
7. LIF: Leukemia Inhibitory Factor
8. AGM: Aorta-Gonad-Mesonephros
9. HSC: Hematopoietic Stem Cell
10. MPP: Multipotent Progenitor
11. CMP: Common Myeloid Progenitor
12. CLP: Common Lymphoid Progenitor
13. Flt3 (-L): FMS-like Tyrosine Receptor 3 (-ligand)
14. MHC proteins: Major Histocompatibility proteins
15. IL7: Interleukin 7
16. DN: CD4 and CD8 Double Negative
17. CD: Cluster of Differentiation
18. DP: CD4 and CD8 Double Positive
19. SP: CD4 or CD8 Single Positive
20. TF(123): Thymic Footprint
21. CTCF: CCCTC Binding Factor
22. qRT-PCR: Quantitative Real Time- Polymerase Chain Reaction
23. LTR: Long Terminal Repeat
24. RRE: Rev Response Element
25. VSV-G: Vesicular Stomatitis Virus Glycoprotein
26. SIN: Self Inactivating
27. cPPT: Central Polypurine Tract
28. WPRE: Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element
29. LNGFR: Low Affinity Nerve Growth Factor Receptor (NTP in constructs)
30. PEG: Polyethylene Glycol
31. IO: Immuno-oncology
32. CRS: Cytokine Release Syndrome
33. IP: Intellectual Property
34. KOL: Key Opinion Leader
35. EL: Entrepreneurial Lead
36. VP: Value Proposition
37. CS: Customer Segment
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List of primers:
hCD2	
  promoter	
  F:	
  5’-GAGGAAACCAACCCCTAAGATGAG-3’	
  
hCD2	
  promoter	
  R:	
  5’-CGTAATCTCTTTGGAGACTGCACC-3’
hCD2	
  qPCR	
  F:	
  5’- CCTTTCTGCTGGTGAACTTGTG-3’	
  
hCD2	
  qPCR	
  R:	
  	
  5’- TCAACACAACCCTGACCTGTG-3’
TCRα	
  qPCR	
  F:	
  5’- AAGATCCTCGGTGTCAGGACA-3’	
  
TCRα	
  qPCR	
  R:	
  5’- AGCAACCTTCCTCACAAATCTG-3’
SV40	
  F:	
  5’-GCGTCGACGCTTAAGATACATTGATGA-3’	
  
SV40	
  R:	
  5’AAGCTCGAGGATCCACCGGATCTA3’
Vα	
  F:	
  5’-AAACCGGTAAGGACGGTAGCATTTTC-3’	
  
Vα	
  R:	
  5’-GGCCATGGACCGGGAGATGTATTC-3’
Transcription unit (TU) F: 5’-GAGGTTGATTGTCGACGCGGTGGCGG3-’
TU R: 5’-CTCGAGAAGCTTGATTACCGGGCCCC3TαLCR4.0 F: 5’-CCGGTGGATCCTCGACTCGAGCTGCA-3’	
  
TαLCR4.0 R: 5’-CGGGCCCCCCCTCGAGCGGCGGCCG-3’
TαLCR1.3 F: F: 5’-CCGGTGGATCCTCGACTCGAGCTGCA-3’
TαLCR1.3 R: 5’-CGGGCCCCCCCTCGAGTACCGCGGCG-3’
pgkNTP replacement F: 5’-CTGAAATCTTGTACAGCTCGTCCATGCC-3’	
  
pgkNTP replacement R: 5’-GAACACGAGGCTCGAGCCCGAGCCCGC-3’
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Table of constructs:
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Supplementary data:

	
  
Supplementary Figure 1: Tables of Mean Fluorescence Intensity (MFI) in co-culture trials for
mini LCR constructs. MFI values were calculated using FlowJo software (Tree Star) from
readout on hCD2-FITC in the indicated cellular subsets. (A). and (B). Tables for TαLCR4.0 and
TαLCR1.3 indicate MFI values obtained in three independent co-culture experiments through
developmental stages (DN1, DN2, DN3, DP [only shown for 2 experiments]), and in both
erythrocyte and monocyte populations. (C). Table for TαLCR2.9 indicates MFI values obtained
in two independent co-culture experiments through developmental stages (DN1, DN2, DN3, DP
[only shown for 1 experiment]), and in both erythrocyte and monocyte populations. (D). Table
for TαLCR3.0 indicates MFI values obtained from preliminary experiments from two
independent co-culture experiments through developmental stages (DN1, DP [only shown for 1
experiment]), and in both erythrocyte and monocyte populations.
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